Primary Sclerosing Cholangitis
Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by progressive inflammation, fibrosis, and stricturing of the intrahepatic and extrahepatic bile ducts, often associated with inflammatory bowel disease.
Primary Sclerosing Cholangitis — let's break down the name first: "primary" = arising on its own (not secondary to another identifiable cause), "sclerosing" = scarring/fibrosis (Greek skleros = hard), "cholangitis" = inflammation of the bile ducts (Greek chole = bile, angeion = vessel, -itis = inflammation). So PSC is a primary, idiopathic chronic progressive cholestatic liver disease characterised by inflammation, obliterative fibrosis, and multifocal stricturing of both the intrahepatic and extrahepatic bile ducts, leading eventually to biliary cirrhosis, portal hypertension, and liver failure [1][2].
The key pathological hallmark is concentric periductal fibrosis ("onion-skin" fibrosis) around medium and large bile ducts, which progressively narrows and obliterates the lumen. This results in cholestasis (impaired bile flow), recurrent bacterial cholangitis, and ultimately end-stage liver disease. There is no known cure apart from liver transplantation.
The term "primary" distinguishes PSC from secondary sclerosing cholangitis — which has an identifiable cause such as surgical trauma, ischaemia, recurrent choledocholithiasis, IgG4-related disease, or recurrent pyogenic cholangitis [1].
Key Concept
PSC is an immune-mediated biliary disease of unknown aetiology that causes progressive stricturing of the biliary tree. Think of it as "autoimmune scarring of the bile ducts." It is the hepatobiliary manifestation most strongly associated with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC).
Epidemiology
- Incidence: ~0.5–1.3 per 100,000 per year in Northern European and North American populations (highest in Scandinavian countries, consistent with the Northern European "IBD belt") [2].
- Prevalence: ~6–16 per 100,000 in Western populations.
- Less primary sclerosing cholangitis with UC in Asian populations — PSC is considerably rarer in East and Southeast Asia, including Hong Kong [3][4]. The IBD lecture slides specifically note "Less primary sclerosing cholangitis with UC" and "Fewer extraintestinal manifestations" in Eastern populations compared to Western populations [3].
- Sex: Male predominance (~2:1, M:F), unlike PBC which overwhelmingly affects women. This is one of the distinguishing epidemiological features.
- Age of onset: Typically diagnosed at age 30–40 years (median ~40), though it can present at any age.
- Earlier onset is seen in patients with concomitant IBD, and in those with PSC-associated cholangiocarcinoma, diagnosis can come as early as the 3rd–4th decade [5].
- In Hong Kong, PSC is uncommon compared to recurrent pyogenic cholangitis (RPC), which is the major biliary disease causing stricturing ("Hong Kong disease") [6].
- When biliary strictures are encountered in an Asian patient, the differential must prominently include RPC, IgG4-associated cholangitis, and parasitic cholangiopathy (Clonorchis sinensis) alongside PSC [2][6].
Exam Pearl
In Asia/Hong Kong, if you see a patient with biliary strictures, think RPC and parasitic causes first. PSC is a diagnosis of exclusion even more so in this population.
| Risk Factor | Mechanism / Explanation |
|---|---|
| Inflammatory bowel disease (IBD) — especially UC | ~60–80% of PSC patients have underlying UC; only ~5% of UC patients develop PSC. The link is hypothesised to involve gut-derived lymphocyte homing to the liver via aberrant expression of adhesion molecules (MAdCAM-1) on hepatic endothelium [1][2] |
| Male sex | 2:1 male predominance; reason unclear but suggests hormonal or genetic modulators |
| Genetic susceptibility | Strong HLA associations — particularly HLA-B8, HLA-DR3 (DRB1*03:01), HLA-DR2 (DRB1*15:01); first-degree relatives have increased risk |
| Smoking | Interestingly, smoking appears to be protective for UC (and by extension may modulate PSC risk), though data for PSC itself are less clear [7] |
| Autoimmune predisposition | Association with other autoimmune conditions (thyroid disease, type 1 DM, coeliac disease) |
| Environmental triggers | Proposed but unproven: gut microbiome dysbiosis, molecular mimicry, toxic bile acid intermediates |
IBD-PSC Association — Know This Cold
- Majority of PSC patients have UC (~60–80%), and some have Crohn's colitis.
- Only ~5% of UC patients have PSC — so screening all IBD patients is not recommended [1].
- PSC can be diagnosed before, concurrently with, or after the diagnosis of IBD. In some cases, PSC is found years after colectomy for UC.
- IBD in PSC patients tends to be pancolitis with rectal sparing and relatively mild colonic symptoms — this is a classic exam trap.
- PSC is a risk factor for IBD-associated colorectal neoplasia [3] — this is why surveillance colonoscopy is yearly in PSC-UC patients.
Anatomy and Function of the Biliary System (Relevant to PSC)
Understanding PSC requires knowing the biliary tree anatomy because the disease involves both intrahepatic and extrahepatic ducts, and the pattern of involvement dictates the clinical presentation and imaging findings.
- Bile canaliculi → formed between adjacent hepatocytes; bile is secreted here
- Canals of Hering (cholangioles) → transitional zone between hepatocytes and bile duct epithelial cells (cholangiocytes); site of hepatic progenitor cells
- Interlobular bile ducts (small intrahepatic ducts, < 100 μm) → within portal triads; these are the target in PBC
- Septal bile ducts → medium-sized intrahepatic ducts
- Segmental bile ducts → drain hepatic segments
- Right and Left hepatic ducts → converge at the hepatic hilum
- Common hepatic duct (CHD) → formed by confluence of R and L hepatic ducts
- Cystic duct → joins from the gallbladder
- Common bile duct (CBD) → CHD + cystic duct → empties into duodenum at ampulla of Vater
- PSC characteristically affects medium and large bile ducts — both intrahepatic and extrahepatic.
- The inflammation and fibrosis occur around the ducts (periductal), leading to progressive luminal narrowing and stricture formation.
- This contrasts with PBC, which targets small intrahepatic (interlobular) bile ducts.
A useful mnemonic: PSC = Plumbing (large ducts); PBC = Petite (small ducts).
- Bile ducts transport bile (containing bile salts, bilirubin, cholesterol, phospholipids) from hepatocytes to the duodenum.
- Cholangiocytes (bile duct epithelial cells) actively modify bile composition by secreting bicarbonate (the "bicarbonate umbrella") and water, and reabsorbing certain solutes.
- When ducts are strictured and scarred → bile stasis → cholestasis → secondary damage to hepatocytes → fibrosis → cirrhosis.
- Bile stasis also predisposes to bacterial cholangitis (ascending infection from duodenum), gallstone formation, and fat-soluble vitamin malabsorption (A, D, E, K).
Aetiology and Pathophysiology
PSC is considered an immune-mediated disease, but it does not fit neatly into the classic "autoimmune" category because:
- It has a male predominance (most autoimmune diseases are female-predominant)
- It does not respond well to immunosuppressive therapy (unlike autoimmune hepatitis or PBC with UDCA)
- No single autoantibody is pathognomonic
The current model involves a "multi-hit" hypothesis:
Pathophysiological Mechanisms (Explained from First Principles)
This is the leading theory linking IBD to PSC:
- In IBD, activated T-lymphocytes in the gut mucosa express surface receptors including α4β7 integrin and CCR9, which normally home to the gut by binding to MAdCAM-1 (mucosal addressin cell adhesion molecule-1) on gut endothelium.
- In PSC, the hepatic endothelium aberrantly expresses MAdCAM-1 and the chemokine CCL25 (normally a gut-specific chemokine). This "tricks" gut-primed T-cells into migrating to the liver and bile ducts.
- These misdirected lymphocytes then mount an immune attack on cholangiocytes → periductal inflammation.
Why does this matter clinically? It explains why PSC can persist or even develop after colectomy — once the aberrant homing pathway is established, it may be self-perpetuating.
- Altered gut microbiome (common in IBD) → changes in bile acid metabolism → production of hydrophobic, toxic bile acids
- These toxic bile acids damage cholangiocyte membranes → inflammation → fibrosis
- Normally, cholangiocytes are protected by a "bicarbonate umbrella" — a layer of alkaline secretion on their apical surface. If this is disrupted (genetic polymorphisms in bile acid transporters or chloride channels like CFTR), bile acids can penetrate and damage cells.
- HLA associations: HLA-B8, HLA-DRB103:01 (DR3), HLA-DRB115:01 (DR2) — these are Class I and Class II MHC molecules that present antigens to T cells; specific alleles may present self-antigens (or cross-reactive microbial antigens) that trigger the immune response.
- Non-HLA genes: polymorphisms in genes related to bile acid transport (e.g., ABCB4), innate immunity, and T-cell regulation have been identified in GWAS studies.
- The hallmark histological finding: concentric rings of collagen deposited around bile ducts, resembling the layers of an onion.
- This is driven by activated portal fibroblasts and hepatic stellate cells responding to chronic inflammation.
- As fibrosis progresses, the duct lumen narrows → stricture.
- Between strictures, bile backs up → duct dilatation → the classic "beaded" appearance on cholangiography.
Once strictures form:
- Bile stasis → impaired excretion of bilirubin (→ jaundice), bile salts (→ pruritus, fat malabsorption), and cholesterol
- Ascending bacterial infection → recurrent cholangitis (because stagnant bile is an excellent culture medium)
- Fat-soluble vitamin deficiency (A, D, E, K) → night blindness, osteoporosis/osteomalacia, neuropathy, coagulopathy
- Hepatocyte injury from retained toxic bile acids → ongoing fibrosis → biliary cirrhosis → portal hypertension → liver failure
Before diagnosing PSC, you must exclude identifiable causes of a similar cholangiographic and histological picture [1]:
| Cause | Key Features |
|---|---|
| IgG4-associated cholangitis (IAC) | Elevated serum IgG4 ( > 135 mg/dL), associated with autoimmune pancreatitis (type 1); responds to corticosteroids (unlike PSC); dense IgG4-positive plasma cell infiltrate on biopsy [1] |
| Recurrent pyogenic cholangitis (RPC) | Intrahepatic pigment stones, strictures predominantly in left hepatic lobe, endemic in Southeast Asia ("Hong Kong disease"), associated with parasitic infection (Clonorchis sinensis) [6] |
| Choledocholithiasis | Stones in CBD causing intermittent obstruction |
| Cholangiocarcinoma | Can mimic PSC or complicate it; must be excluded especially if dominant stricture present |
| Surgical / ischaemic biliary stricture | History of hepatic artery thrombosis (post-transplant), biliary surgery, critical illness cholangiopathy |
| HIV cholangiopathy | AIDS-related; opportunistic infections (CMV, Cryptosporidium) causing biliary strictures |
| Chronic bacterial cholangitis | Recurrent infections from structural abnormalities |
| Autoimmune hepatitis-PSC overlap | Features of both AIH (elevated transaminases, positive ANA/SMA, interface hepatitis) and PSC; important to recognise because it responds to immunosuppression [1] |
IgG4 Cholangitis vs PSC
This is a critical distinction: IgG4-associated cholangitis responds to corticosteroids while PSC does not. Always check serum IgG4 in a patient with sclerosing cholangitis. IgG4-associated disease has a more rapidly progressive course if untreated [1].
Classification
| Type | Description | Notes |
|---|---|---|
| Classic PSC | Involvement of large intrahepatic and/or extrahepatic ducts | Visible on MRCP/ERCP; most common form (~95%) |
| Small-duct PSC | Only small intrahepatic ducts involved | Normal cholangiogram; diagnosed on liver biopsy showing characteristic histology; better prognosis than classic PSC; may progress to large-duct PSC in ~20% |
| Type | Description |
|---|---|
| PSC with IBD | ~60–80% of cases; usually UC (pancolitis with rectal sparing); occasionally Crohn's colitis |
| PSC without IBD | ~20–40%; may have subclinical colonic inflammation on biopsy even without clinical IBD |
| PSC-AIH overlap | Features of both conditions; more common in children/young adults; responds to immunosuppression |
- Intrahepatic only (~25%)
- Extrahepatic only (~5%)
- Both intrahepatic and extrahepatic (~70%) — most common pattern
Clinical Features
PSC is insidious. Up to 50% of patients are asymptomatic at diagnosis [1], often detected incidentally through abnormal liver function tests (particularly elevated ALP) during evaluation of IBD. The median time from diagnosis to liver transplantation or death is approximately 12–18 years without transplantation.
| Symptom | Mechanism |
|---|---|
| Pruritus | Cholestasis → retained bile salts and pruritogens (lysophosphatidic acid, autotaxin) deposited in skin → stimulation of itch-mediating neurons. One of the earliest and most distressing symptoms. Pruritus is a common symptom resulting from cholestasis and can lead to severe excoriations [1] |
| Fatigue | Multifactorial: cholestasis-related central neurotransmitter changes (altered serotonergic/hypothalamic signalling), sleep disruption from pruritus, chronic inflammation. Fatigue is a common symptom in patients who are symptomatic [1] |
| Right upper quadrant (RUQ) discomfort | Hepatomegaly stretching Glisson's capsule; or biliary duct distension proximal to strictures [1] |
| Jaundice | Biliary obstruction from strictures → impaired bilirubin excretion → conjugated hyperbilirubinaemia. May fluctuate: Bilirubin may fluctuate substantially, possibly indicating transient blockage of strictured bile ducts by biliary sludge or small stones [1] |
| Fever and rigors | Episodes of bacterial cholangitis: bile stasis → ascending infection from duodenum → bacteraemia. Organisms: Gram-negative rods (E. coli, Klebsiella) > Enterococcus [2] |
| Night sweats | Part of constitutional symptoms along with fever, chills, and weight loss [1]; reflects systemic inflammatory burden |
| Weight loss | Chronic cholestasis → fat malabsorption (bile salts not reaching duodenum) → caloric loss in stool. Also cytokine-driven catabolism |
| Steatorrhoea | Impaired fat digestion due to reduced bile salt delivery to the duodenal lumen → foul-smelling, greasy, floating stools |
| Dark urine (tea-coloured) | Conjugated bilirubin is water-soluble → filtered by kidneys → dark urine when serum conjugated bilirubin is elevated [8] |
| Pale stools (acholic) | Reduced bilirubin reaching the gut (normally converted to stercobilin, which gives stool its brown colour) → pale/clay-coloured stools [8] |
- Asymptomatic at diagnosis = 50% and detected as part of the evaluation of abnormal liver tests in patients with IBD [1].
- The typical scenario: a young male with known UC has routine blood work showing a persistently elevated ALP → MRCP → beaded bile ducts → PSC diagnosed.
| Sign | Mechanism |
|---|---|
| Jaundice (scleral icterus → generalised) | Conjugated hyperbilirubinaemia; clinically detectable when serum bilirubin > 50 μmol/L. Yellowing of sclera and skin [8] |
| Excoriations | Scratch marks from chronic pruritus due to cholestasis. Excoriations on examination [1] |
| Hepatomegaly | Cholestasis → bile duct dilatation and periportal inflammation/fibrosis → liver enlargement. Hepatomegaly [1] |
| Splenomegaly | Develops with portal hypertension from biliary cirrhosis → splenic congestion. Splenomegaly [1] |
| Xanthomata / Xanthelasma | Chronic cholestasis → impaired cholesterol excretion → hypercholesterolaemia → lipid deposition in skin (xanthomata) and periorbital tissue (xanthelasma) |
| Signs of chronic liver disease | As disease progresses to cirrhosis: spider naevi, palmar erythema, gynaecomastia, testicular atrophy, caput medusae, Dupuytren's contracture, leuconychia, clubbing |
| Signs of portal hypertension | Ascites (transudative, due to sinusoidal hypertension + hypoalbuminaemia), splenomegaly, caput medusae, oesophageal varices (detected on OGD, not on physical exam per se) |
| Signs of fat-soluble vitamin deficiency | Osteoporosis/bone tenderness (vitamin D → osteomalacia), bruising/bleeding (vitamin K → coagulopathy), night blindness (vitamin A), peripheral neuropathy (vitamin E) |
| Stigmata of associated IBD | Erythema nodosum, pyoderma gangrenosum, oral aphthous ulcers, peripheral arthropathy, sacroiliitis (if ankylosing spondylitis associated) |
| Courvoisier's sign | NOT expected in PSC (Courvoisier's sign = palpable non-tender gallbladder in painless obstructive jaundice; implies distal CBD obstruction by tumour, not intrahepatic/hilar disease) |
Clinical Pearl — Dominant Stricture
A dominant stricture is defined as a stricture with a diameter of ≤1.5 mm in the common bile duct or ≤1.0 mm in a hepatic duct. It occurs in ~50% of PSC patients during their disease course. Clinically, a dominant stricture may cause:
- Acute worsening of jaundice
- New-onset or worsening pruritus
- Episodes of bacterial cholangitis
- Rapidly rising bilirubin
This must raise concern for cholangiocarcinoma superimposed on PSC — brush cytology at ERCP is required to exclude malignancy.
PSC doesn't exist in isolation. The associated conditions are high-yield:
| Association | Details |
|---|---|
| Ulcerative colitis | ~60–80% of PSC patients; strong association between PSC and UC [1]. UC in PSC tends to be pancolitis with rectal sparing, backwash ileitis, mild symptoms |
| Crohn's disease | ~10% of PSC patients have Crohn's colitis |
| Cholangiocarcinoma | Lifetime risk ~10–20%; PSC is the strongest risk factor for cholangiocarcinoma [5][9]. Risk is highest in the first 1–2 years after PSC diagnosis |
| Colorectal cancer | PSC is a risk factor for IBD-associated colorectal neoplasia [3]; CRC risk is 4–5× higher in PSC-UC than UC alone; annual colonoscopy recommended from time of PSC diagnosis |
| Gallbladder carcinoma | Increased risk; PSC is listed as a risk factor for gallbladder cancer [9][10]; gallbladder polyps ≥ 8 mm in PSC warrant cholecystectomy (lower threshold than general population's 10 mm) |
| Hepatocellular carcinoma | Risk is increased if cirrhosis develops; PSC is listed under autoimmune causes of HCC [11] |
| Pancreatic carcinoma | Slightly increased risk |
| Metabolic bone disease | Osteoporosis > osteomalacia; due to chronic cholestasis and fat-soluble vitamin D malabsorption |
| Fat-soluble vitamin deficiency | A, D, E, K — see above |
Cancer Surveillance in PSC
This is critical for exams and real life:
- Cholangiocarcinoma: Annual MRCP + CA 19-9 monitoring (though CA 19-9 has limited sensitivity/specificity); any dominant stricture → ERCP with brush cytology ± fluorescence in situ hybridization (FISH)
- Colorectal cancer: Primary sclerosing cholangitis → yearly surveillance colonoscopy [3] — this is a separate, more aggressive schedule than standard IBD surveillance. PSC is a disease-specific risk factor for IBD-associated colorectal neoplasia [3].
- Gallbladder cancer: Annual ultrasound; cholecystectomy for polyps ≥ 8 mm (vs 10 mm in general population)
These lab findings are part of the clinical picture that will lead you toward the diagnosis:
| Test | Finding | Explanation |
|---|---|---|
| ALP | ↑↑ (predominantly elevated) | ALP is released from damaged cholangiocytes and from the canalicular membrane under cholestatic conditions. ALP is the predominantly elevated enzyme [1] |
| GGT | ↑↑ | Co-elevated with ALP in cholestasis; GGT is induced by bile acids and alcohol |
| AST / ALT | Normal or mildly elevated | Serum aminotransferases are typically less than 300 IU/L [1]. If markedly elevated (>5× ULN), consider PSC-AIH overlap or concurrent hepatitis |
| Bilirubin | Normal or elevated; may fluctuate | Bilirubin may fluctuate substantially [1] — a transient rise may indicate biliary sludge or stone temporarily blocking a stricture |
| Albumin | Normal in early disease; low in advanced disease | Serum albumin is normal in patients with early stage disease but those with active IBD may have hypoalbuminaemia [1]; progressive decrease with advancing fibrosis/cirrhosis (impaired hepatic synthetic function) |
| AMA | Typically absent | AMA is typically absent in PSC — its presence suggests PBC or overlap syndrome [1] |
| IgG4 | May be elevated in ~9–15% | Must check to exclude IgG4-associated cholangitis; IgG4-associated disease has a more rapidly progressive course and appears to be less likely to respond to corticosteroids (note: this is the opposite — IgG4 disease DOES respond to steroids; the notes seem to have an error; AASLD/EASL guidelines confirm IgG4-SC responds to steroids, while PSC does not) [1] |
| Serum IgM | ↑ (40–50%) | Non-specific; also elevated in PBC |
| Hypergammaglobulinaemia | Present in ~30% | Polyclonal IgG elevation reflecting chronic immune activation |
| p-ANCA | Positive in 30–80% | Atypical perinuclear ANCA (pANCA); also seen in UC; not specific but supportive. The target antigen is likely beta-tubulin isotype 5 |
| INR / PT | Prolonged in advanced disease | Impaired hepatic synthesis of clotting factors (especially Factors II, VII, IX, X — vitamin K dependent) |
ALP Disproportionately Elevated
The classic biochemical pattern in PSC: ALP is disproportionately elevated relative to transaminases. If you see a young male with IBD and an ALP 3–10× ULN with near-normal ALT/AST, PSC should be at the top of your list.
| Pathophysiology | → | Clinical Feature |
|---|---|---|
| Periductal fibrosis → strictures | → | Beaded bile ducts on imaging |
| Strictures → bile stasis | → | Cholestasis (elevated ALP, GGT, bilirubin) |
| Cholestasis → retained bile salts | → | Pruritus, excoriations |
| Cholestasis → impaired bilirubin excretion | → | Jaundice, dark urine, pale stools |
| Cholestasis → fat malabsorption | → | Steatorrhoea, weight loss, fat-soluble vitamin deficiency |
| Vitamin K deficiency | → | Coagulopathy (bruising, bleeding) |
| Vitamin D deficiency | → | Osteoporosis, osteomalacia |
| Bile stasis → ascending infection | → | Recurrent bacterial cholangitis (fever, rigors) |
| Progressive fibrosis → cirrhosis | → | Portal hypertension (ascites, varices, splenomegaly) |
| Cirrhosis → hepatocellular dysfunction | → | Hypoalbuminaemia, coagulopathy, encephalopathy |
| Chronic biliary inflammation | → | Cholangiocarcinoma risk (10–20% lifetime) |
| Immune-mediated + gut-liver axis | → | Association with IBD (UC >> CD) |
| IBD + PSC | → | Increased colorectal cancer risk |
High Yield Summary
-
Definition: PSC is a chronic, progressive, immune-mediated cholestatic liver disease characterised by multifocal stricturing and fibrosis of intrahepatic and extrahepatic bile ducts, leading to biliary cirrhosis.
-
Epidemiology: Male predominance (2:1), age 30–40, much more common in Western/Northern European populations. Less common in Asia, including Hong Kong [3].
-
IBD association: ~60–80% have UC; only ~5% of UC patients develop PSC. IBD in PSC tends to be pancolitis with rectal sparing.
-
Pathophysiology: Gut-liver axis → aberrant lymphocyte homing (MAdCAM-1) → periductal "onion-skin" fibrosis → multifocal strictures → cholestasis → biliary cirrhosis.
-
Clinical features: 50% asymptomatic at diagnosis. Key symptoms: pruritus, fatigue, RUQ pain, fluctuating jaundice, recurrent cholangitis. Key signs: hepatomegaly, splenomegaly, excoriations, jaundice, signs of chronic liver disease.
-
Biochemistry: Cholestatic pattern — ALP disproportionately elevated, normal/mild AST/ALT elevation, AMA negative (distinguishes from PBC), p-ANCA often positive.
-
Cancer risk: Cholangiocarcinoma (10–20% lifetime), CRC (4–5× increased in PSC-UC → annual colonoscopy), gallbladder cancer.
-
Exclude secondary causes: IgG4-associated cholangitis (responds to steroids!), RPC, choledocholithiasis, HIV cholangiopathy, ischaemic cholangiopathy.
-
No cure except liver transplantation. UDCA is controversial and not proven to alter natural history.
Active Recall - PSC (Definition, Epidemiology, Pathophysiology, Clinical Features)
[1] Senior notes: felixlai.md (Primary Sclerosing Cholangitis section, felix:756–757) [2] Senior notes: maxim.md (Acute cholangitis section, maxim:288) [3] Lecture slides: Inflammatory bowel disease.pdf (p5, p9, p52, p56) [4] Lecture slides: Inflammatory bowel disease.pdf (p5 — East vs West comparison) [5] Senior notes: felixlai.md (Cholangiocarcinoma epidemiology, felix:777) [6] Senior notes: maxim.md (Recurrent pyogenic cholangitis, maxim:290) [7] Senior notes: felixlai.md (UC risk factors — smoking protective, felix:975) [8] Senior notes: maxim.md (Obstructive jaundice section, maxim:251–252) [9] Senior notes: felixlai.md (Cholangiocarcinoma risk factors, felix:778) [10] Senior notes: felixlai.md (Gallbladder cancer risk factors, felix:801) [11] Senior notes: felixlai.md (HCC risk factors — autoimmune liver diseases, felix:682)
Differential Diagnosis of Primary Sclerosing Cholangitis
Before we list the differentials, let's understand the clinical scenario you're actually working with. A patient with PSC typically presents with one or more of the following:
- Cholestatic liver biochemistry — elevated ALP/GGT out of proportion to transaminases
- Biliary strictures on imaging — multifocal strictures with segmental dilatation on MRCP/ERCP
- Clinical cholestasis — jaundice, pruritus, dark urine, pale stools
- Known IBD with incidental abnormal LFTs
The differential diagnosis therefore needs to address two overlapping clinical questions:
- What else causes a cholestatic biochemical pattern?
- What else causes biliary strictures on cholangiography?
These are not the same list, and the approach differs depending on which "entry point" brought the patient to your attention.
I like to organise this by thinking about what level of the biliary tree is affected and what mechanism is causing the damage. This mirrors how you'll actually reason at the bedside.
Detailed Differential Diagnosis
These are the "secondary sclerosing cholangitis" mimics — conditions that produce a cholangiographic picture similar to PSC but have an identifiable cause [1][2].
| Condition | Key Distinguishing Features | Why It Mimics PSC |
|---|---|---|
| IgG4-associated cholangitis (IAC) | Elevated serum IgG4 > 135 mg/dL; mostly elderly male; associated with autoimmune pancreatitis type 1; dense IgG4+ plasma cell infiltrate on biopsy; responds to corticosteroids (PSC does not) [2] | Causes multifocal biliary strictures involving intrahepatic and extrahepatic ducts, can look identical to PSC on MRCP |
| Recurrent pyogenic cholangitis (RPC) | "Hong Kong disease"; intrahepatic pigment stones and intrahepatic biliary obstruction; usually starts in left intrahepatic ducts; associated with parasitic infection (Clonorchis sinensis); equal M:F; peak in 30–40s [6][12] | Causes intrahepatic strictures with dilated ducts; but key difference: stones are present within bile ducts (brown pigment/calcium bilirubinate), strictures predominantly left-sided, history of recurrent cholangitis episodes |
| Cholangiocarcinoma | Adenocarcinoma of bile duct ( > 90%); association with ulcerative colitis (common in Westerners) and recurrent pyogenic cholangitis (common in Orientals); raised CA 19-9 (though non-specific); mostly occurs in patients > 50 years [9][13][14] | Can produce a dominant stricture that mimics PSC; in fact, cholangiocarcinoma can arise within PSC (10–20% lifetime risk). Any new dominant stricture in a PSC patient must be investigated with brush cytology |
| Choledocholithiasis | Intermittent obstructive jaundice with pain; stone visible on USG/MRCP; stone causes painful jaundice (vs painless in tumour) [8][15] | CBD stones can cause localised strictures from chronic inflammation, but the pattern is focal, not multifocal |
| Surgical / ischaemic biliary trauma | History of cholecystectomy, liver transplantation (hepatic artery thrombosis), or critical illness (ICU cholangiopathy) | Ischaemic injury to peribiliary vascular plexus → bile duct necrosis → strictures. Distribution often follows vascular territory rather than the "beaded" pattern of PSC |
| HIV cholangiopathy | Advanced HIV/AIDS (CD4 < 100); caused by opportunistic infections — CMV, Cryptosporidium, Microsporidium | Papillary stenosis + intrahepatic sclerosing cholangitis pattern; responds to HAART and treatment of opportunistic infection |
| Recurrent pancreatitis | History of recurrent acute pancreatitis; stricture typically involves distal CBD (intrapancreatic portion) | Chronic pancreatic inflammation → fibrosis around the intrapancreatic CBD → distal stricture. Focal, not multifocal |
| Chronic bacterial cholangitis | Recurrent biliary infections from structural abnormalities (post-surgical, biliary-enteric anastomosis) | Repeated infection → chronic inflammation → strictures. History is key |
RPC vs PSC — A Hong Kong Favourite
This distinction is extremely high-yield for HKU exams:
| Feature | PSC | RPC |
|---|---|---|
| Geography | Western > > Asian | Southeast Asia ("Hong Kong disease") [6] |
| Sex | Male predominance (2:1) | Equal M:F |
| Stones | Not a primary feature | Intrahepatic pigment/calcium bilirubinate stones — formed de novo in ducts |
| Duct preference | Both intrahepatic + extrahepatic | Left intrahepatic ducts predominantly |
| Stricture type | Multifocal, beaded, both intra- and extrahepatic | Focal areas of stricturing with stone-related dilatation |
| IBD association | 60–80% have UC | None |
| Parasites | Not associated | Clonorchis sinensis, Opisthorchis viverrini |
| Pathogenesis | Immune-mediated periductal fibrosis | Stasis + Stricturing + Recurrent infection cycle [6] |
These conditions present with elevated ALP/GGT but may not produce biliary strictures visible on cholangiography.
| Condition | Key Distinguishing Features | Why It's in the DDx |
|---|---|---|
| Primary biliary cholangitis (PBC) | Extreme female predominance (90–95%); age 30–65; AMA positive at titre ≥ 1:40; targets small intralobular bile ducts (not visible on MRCP); associated with Sjögren's, scleroderma, Hashimoto's [16] | Both cause cholestatic LFTs (elevated ALP/GGT), pruritus, fatigue, and eventually cirrhosis. The cholangiogram is normal in PBC (small ducts not visible on MRCP). AMA is the key serological discriminator |
| PSC-AIH overlap syndrome | Features of both PSC (biliary strictures) and AIH (elevated transaminases > 5× ULN, positive ANA/SMA, interface hepatitis on biopsy); more common in children/young adults [1] | Important to recognise because it responds to immunosuppression (corticosteroids ± azathioprine), unlike pure PSC |
| Drug-induced cholestasis | Temporal association with offending drug; common culprits: amoxicillin-clavulanate, erythromycin, anabolic steroids, oral contraceptives, chlorpromazine | Drugs can cause bland cholestasis (no hepatocyte damage) or cholestatic hepatitis. No biliary strictures on imaging. Resolves with drug withdrawal |
| Viral hepatitis (cholestatic phase) | Acute hepatitis A/E can have a cholestatic phase; HBV/HCV can cause cholestatic flares; serology positive [15] | Transaminases usually markedly elevated (>10× ULN) alongside cholestatic enzymes — this is not the PSC pattern where ALP dominates |
| Alcoholic hepatitis / Alcoholic liver disease | History of heavy alcohol use; AST:ALT ratio > 2:1 ("De Ritis ratio"); elevated GGT; may have cholestatic pattern in severe cases [15] | Can cause cholestatic LFTs; history and the typical AST > ALT pattern differentiate |
| Non-alcoholic steatohepatitis (NASH) | Metabolic syndrome; obesity; USS shows fatty liver; liver biopsy shows steatohepatitis, ballooning | Occasionally presents with mildly elevated ALP; usually hepatitic pattern predominates |
| Sarcoidosis | Non-caseating granulomas; elevated ACE; bilateral hilar lymphadenopathy on CXR; granulomatous hepatitis | Hepatic sarcoidosis can produce cholestatic LFTs and even intrahepatic cholestasis mimicking PBC or small-duct PSC |
| Infiltrative liver diseases | Amyloidosis, lymphoma, metastatic disease; ALP markedly elevated | Infiltration of hepatic parenchyma → elevated ALP; imaging usually shows hepatomegaly ± focal lesions rather than biliary strictures |
| Condition | Key Features |
|---|---|
| PSC-AIH overlap | ~5–10% of PSC patients; defined by elevated IgG, positive ANA or SMA, and interface hepatitis on liver biopsy superimposed on cholangiographic PSC. Reserved for patients with suspected small duct PSC or if an overlap syndrome with autoimmune hepatitis are suspected — this is when liver biopsy is indicated [1] |
| IgG4-associated sclerosing cholangitis | Can coexist with or mimic PSC; serum IgG4 is a characteristic marker of autoimmune pancreatitis but is also elevated in patients with PSC (~9–15% of PSC patients have elevated IgG4 without having true IgG4-SC) [1] |
| Small-duct PSC | Normal MRCP/ERCP but histological features of PSC on liver biopsy; presents with cholestatic LFTs ± IBD; better prognosis; ~20% progress to large-duct PSC |
This is how surgeons think about it — based on where the obstruction is on imaging [8][15]:
| Level of Obstruction | Differential Diagnoses |
|---|---|
| Hilum | CA Gallbladder, HCC, Klatskin's tumour, Mirizzi syndrome, Porta lymphadenopathy, PSC, RPC [8] |
| Mid-CBD | CA CBD, CA Head of pancreas, Lymphadenopathy [8] |
| Distal CBD | Bile duct strictures, Periampullary carcinoma, Choledochal cysts, Pancreatic cysts, Chronic pancreatitis [8] |
This comparison comes up in virtually every hepatology exam. Know it cold.
| Feature | PSC | PBC |
|---|---|---|
| Sex | Male (2:1) | Female (90–95%) [16] |
| Age | 30–40 | 30–65 |
| Duct size affected | Medium and large (intra + extrahepatic) | Small intralobular |
| Cholangiogram | "Beaded" strictures (MRCP/ERCP) | Normal (ducts too small to see) |
| AMA | Typically absent [1] | Positive ≥ 1:40 (>95%) [16] |
| p-ANCA | Positive (30–80%) [1] | Usually negative |
| ANA/SMA | Variable | May be positive (~50%) |
| IgM | Elevated (40–50%) [1] | Markedly elevated |
| IBD association | Strong (UC 60–80%) [1] | None |
| Associated conditions | UC, cholangiocarcinoma, CRC | Sjögren's, scleroderma, Hashimoto's, RA [16] |
| Response to UDCA | Controversial; does NOT alter natural history | Proven benefit; slows progression |
| Histology | "Onion-skin" periductal fibrosis | Non-suppurative destructive cholangitis (florid duct lesion) |
| Malignancy risk | Cholangiocarcinoma (10–20%), CRC, GB cancer | Low |
| Liver transplantation | Definitive treatment; but can recur post-transplant (~20%) | Definitive treatment; recurrence uncommon |
When a PSC patient develops worsening jaundice, you need to determine whether it's from the PSC itself (dominant stricture), a superimposed stone, or — critically — a cholangiocarcinoma. The classic stone vs tumour distinction applies [8][15]:
| Feature | Stone | Tumour |
|---|---|---|
| Jaundice | Intermittent (stone may pass) | Progressive |
| Pain | Painful (stone passing through ampulla) | Painless (until advanced); except CA pancreatic head: well innervated, spread to coeliac ganglion early [15] |
| Fever/infection | More likely (bile stasis → ascending infection) | Until late stage |
| Constitutional symptoms | Absent | LOW, LOA, night sweats [15] |
| Courvoisier's sign | Negative (chronic inflammation → fibrotic, non-distensible GB) | Positive if distal obstruction |
"Painless progressive obstructive jaundice in elderly is malignant biliary obstruction until proven otherwise" [8].
Exam Trap — Dominant Stricture in PSC
A dominant stricture in PSC does NOT automatically mean cholangiocarcinoma, but it must be investigated to exclude it. The approach: ERCP with brush cytology ± FISH (fluorescence in situ hybridization). CA 19-9 is supportive but non-specific (also elevated in benign cholestasis and other GI cancers). Cholangiocarcinoma is characterised by slow growth, high rate of local invasion, mucin production and tendency to invade perineural sheath and spread along nerves [9].
When you're working up a patient and PSC is on your differential, these history points help you narrow down [8][15]:
| History Point | What It Helps Differentiate |
|---|---|
| PMH: IBD | Strongly supports PSC; IBD is a risk factor for PSC [15] |
| PMH: Gallstones | Choledocholithiasis, Mirizzi syndrome |
| PMH: Hepatitis B carrier | HCC with biliary invasion, or concurrent CLD |
| PMH: Previous biliary surgery | Iatrogenic stricture, secondary sclerosing cholangitis |
| PMH: Autoimmune conditions | PBC (Sjögren's, scleroderma); PSC-AIH overlap |
| Drug history | Drug-induced cholestasis |
| SH: Smoking, alcohol | Alcoholic liver disease; note smoking is protective for UC [15] |
| SH: Raw freshwater fish consumption | Clonorchis sinensis → RPC / cholangiocarcinoma risk [12] |
| FH: CRC | Lynch syndrome (increased cholangiocarcinoma risk) [9] |
| Travel / origin | Southeast Asia → RPC; Northern Europe → PSC more common |
The 3-Step Approach to Cholestatic LFTs
- Check AMA → If positive, think PBC
- If AMA negative → MRCP → Multifocal strictures = PSC; normal = small-duct PSC or other intrahepatic cause
- Check IgG4 → Elevated = consider IgG4-associated cholangitis (treatable with steroids!)
Always exclude secondary causes (RPC, surgical trauma, choledocholithiasis, cholangiocarcinoma) before labelling someone with "primary" sclerosing cholangitis.
High Yield Summary — Differential Diagnosis
-
PSC is a diagnosis of exclusion — you must rule out secondary sclerosing cholangitis (IgG4-SC, RPC, ischaemic, surgical, HIV cholangiopathy, stones, tumour).
-
IgG4-associated cholangitis is the most critical mimic to exclude because it responds to steroids. Always check serum IgG4.
-
PBC vs PSC: AMA positive = PBC; AMA negative + biliary strictures on MRCP = PSC. PBC affects small ducts (normal cholangiogram); PSC affects large ducts (beaded cholangiogram).
-
RPC vs PSC (Hong Kong context): RPC = intrahepatic pigment stones, left lobe predominance, parasitic association, no IBD link. PSC = immune-mediated, beaded bilateral strictures, UC association.
-
Dominant stricture in PSC must always be investigated to exclude cholangiocarcinoma — use ERCP with brush cytology ± FISH.
-
Stone vs tumour: Stone = intermittent, painful jaundice with fever. Tumour = progressive, painless jaundice with constitutional symptoms.
-
PSC-AIH overlap (~5–10%): suspect if transaminases markedly elevated; responds to immunosuppression — don't miss it.
-
Obstructive jaundice DDx by level: Hilum (PSC, RPC, Klatskin's, HCC, Mirizzi, CA GB); Mid-CBD (CA CBD, CA pancreas head); Distal CBD (periampullary CA, choledochal cyst, chronic pancreatitis).
Active Recall - PSC Differential Diagnosis
References
[1] Senior notes: felixlai.md (Primary Sclerosing Cholangitis section, felix:756–757) [2] Senior notes: maxim.md (Acute cholangitis section, maxim:288) [6] Senior notes: maxim.md (Recurrent pyogenic cholangitis, maxim:290) [8] Senior notes: maxim.md (Obstructive jaundice section, maxim:251–252) [9] Senior notes: felixlai.md (Cholangiocarcinoma risk factors and pathogenesis, felix:778–779) [12] Senior notes: felixlai.md (Recurrent pyogenic cholangitis, felix:752) [13] Lecture slides: WCS 064 - A large liver - by Prof R Poon [20191108].doc.pdf (p5 — Cholangiocarcinoma) [14] Senior notes: maxim.md (Cholangiocarcinoma, maxim:294) [15] Senior notes: maxim.md (Obstructive jaundice — stone vs tumour, maxim:252) [16] Senior notes: felixlai.md (Primary biliary cholangitis, felix:760)
Diagnostic Criteria for PSC
Here's the thing about PSC that makes it different from many other conditions: there is no single pathognomonic test. There is no "AMA for PBC" equivalent. The diagnosis is established by combining clinical, biochemical, cholangiographic, and sometimes histological data — and critically, by excluding secondary causes of sclerosing cholangitis. Think of it as a constructive diagnosis rather than a "one-test rules them all" diagnosis.
The diagnosis of PSC is established when ALL THREE of the following are met:
| Criterion | Details | Why This Criterion Exists |
|---|---|---|
| 1. Cholestatic biochemistry | Elevated ALP (typically > 1.5× ULN) persisting for > 6 months | ALP elevation is the biochemical hallmark of biliary injury. It must be persistent — a transient ALP rise could be from many causes (e.g., drugs, pregnancy, bone disease). The 6-month threshold ensures chronicity |
| 2. Characteristic cholangiographic findings | Multifocal strictures alternating with dilatation (the "beaded" pattern) on MRCP (preferred) or ERCP, involving intrahepatic and/or extrahepatic bile ducts | This is the cornerstone of diagnosis. The stricture-dilatation pattern is virtually diagnostic when combined with the right clinical context. MRCP is typically the 1st imaging modality due to non-invasiveness and comparable diagnostic accuracy to ERCP [1] |
| 3. Exclusion of secondary causes | Must rule out: IgG4-associated cholangitis, ischaemic cholangiopathy, surgical/traumatic strictures, choledocholithiasis, cholangiocarcinoma, RPC, HIV cholangiopathy, congenital biliary anomalies | PSC is "primary" — by definition, it has no identifiable external cause. You cannot diagnose PSC without actively excluding the mimics [1] |
Small-Duct PSC — The Exception
Small-duct PSC is diagnosed when a patient has:
- Cholestatic biochemistry (elevated ALP)
- Normal MRCP and ERCP (because the affected ducts are too small to visualise on cholangiography)
- Liver biopsy showing characteristic histological features of PSC (periductal concentric "onion-skin" fibrosis)
- Exclusion of PBC (AMA negative) and other causes
Liver biopsy is reserved for patients with suspected small duct PSC or if an overlap syndrome with autoimmune hepatitis are suspected [1]. This is one of the few situations where biopsy is essential in PSC workup.
Understanding both side-by-side helps cement why the approach differs:
| Feature | PSC Diagnosis | PBC Diagnosis |
|---|---|---|
| Biochemistry | ALP > 1.5× ULN for > 6 months | ALP ≥ 1.5× ULN [16] |
| Key serological test | AMA typically absent [1]; p-ANCA supportive but not diagnostic | AMA positive ≥ 1:40 (95% sensitive) [16] |
| Imaging | MRCP/ERCP showing multifocal strictures — this IS the diagnostic test | Normal cholangiogram (small ducts not visualised) |
| Biopsy | Not routinely needed (except small-duct PSC, overlap syndrome) | Needed only if AMA negative and ALP elevated — then biopsy shows non-suppurative destructive cholangitis [16] |
| Diagnosis requires | Cholangiography + exclusion of secondary causes | ≥ 2 of: ALP elevation, AMA positivity, histological evidence [16] |
Here is the step-by-step clinical reasoning pathway. The key principle: start with blood tests → serology → imaging → biopsy only if needed.
The 5-Step Diagnostic Algorithm — Simplified
- Confirm cholestatic pattern → ALP > > ALT
- Check AMA → If positive = PBC; if negative → proceed
- MRCP → Beaded strictures = PSC; normal = consider small-duct PSC (biopsy needed)
- Check IgG4 → Elevated = IgG4-SC (responds to steroids); normal = confirms PSC
- Mandatory workup → Colonoscopy (IBD screen), bone density, fat-soluble vitamins, cancer surveillance
Investigation Modalities — Detailed Breakdown
A. Biochemical Tests (Blood Work)
| Parameter | Expected in PSC | Interpretation / Pathophysiological Basis |
|---|---|---|
| ALP | ↑ (predominantly elevated) | ALP is anchored to the canalicular membrane of hepatocytes and cholangiocytes. In cholestasis, bile acids solubilise ALP from the membrane → released into blood. Also, bile duct obstruction upregulates ALP gene expression. ALP is the predominantly elevated enzyme in PSC [1] |
| GGT | ↑↑ | GGT is present on the surface of cholangiocytes and hepatocytes. Like ALP, it is induced by cholestasis and also by alcohol. Elevation of GGT can confirm excess ALP is of hepatobiliary origin (as opposed to bone-origin ALP, which would have normal GGT) [17] |
| AST / ALT | Normal or mildly elevated (< 300 IU/L) | Serum aminotransferases are typically less than 300 IU/L [1]. Mild elevation reflects secondary hepatocyte damage from retained toxic bile acids. If markedly elevated ( > 5× ULN), suspect PSC-AIH overlap or concurrent viral hepatitis |
| Bilirubin | Normal or elevated; may fluctuate | Bilirubin may fluctuate substantially, possibly indicating transient blockage of strictured bile ducts by biliary sludge or small stones [1]. A steadily rising bilirubin is ominous — think cholangiocarcinoma or progressive disease |
| Albumin | Normal in early disease; decreased in advanced disease | Serum albumin is normal in patients with early stage disease but those with active IBD may have hypoalbuminaemia [1]. Half-life of albumin is ~20 days, so it reflects chronic synthetic function |
| PT / INR | Normal or prolonged | Prolonged in advanced disease due to: (a) impaired hepatic synthesis of clotting factors, and (b) vitamin K malabsorption from cholestasis. Always check if correctable with vitamin K — if it corrects, the issue is malabsorption, not synthetic failure |
Clinical Pearl: A cholestatic pattern means ALP/GGT elevated out of proportion to ALT/AST. In PSC, the typical picture is ALP 3–10× ULN with ALT < 2× ULN. If the transaminases dominate, reconsider the diagnosis.
| Test | Expected in PSC | Clinical Significance |
|---|---|---|
| AMA (Anti-mitochondrial antibody) | Typically absent [1] | The single most important serological test to exclude PBC. AMA is typically absent in PSC and is required to help exclude primary biliary cholangitis [1]. If AMA is positive in a patient with biliary strictures, consider overlap syndrome or coexistent PBC |
| p-ANCA (Perinuclear ANCA) | Positive in 30–80% [1] | Atypical p-ANCA (target antigen: beta-tubulin isotype 5 or nuclear envelope proteins). Also positive in UC. Supportive but not diagnostic — it is neither sensitive nor specific enough to diagnose PSC alone. Think of it as a clue, not a proof |
| ANA / SMA | Variable (positive in ~25–50%) | If both are strongly positive with markedly elevated IgG and transaminases, suspect PSC-AIH overlap syndrome |
| Serum IgM | Elevated in 40–50% [1] | Non-specific polyclonal IgM elevation; also seen in PBC. Reflects chronic immune stimulation |
| Hypergammaglobulinaemia | Present in ~30% [1] | Polyclonal IgG elevation reflecting chronic hepatic immune activation and impaired clearance of gut-derived antigens by the diseased liver |
| Serum IgG4 | Normal in most; elevated in ~9–15% | Serum IgG4 is a characteristic marker of autoimmune pancreatitis but is also elevated in patients with PSC [1]. Critical to distinguish true IgG4-associated cholangitis from PSC with incidentally elevated IgG4. If IgG4 > 4× ULN → strongly consider IgG4-SC → trial of corticosteroids |
The IgG4 Conundrum
About 9–15% of PSC patients have mildly elevated IgG4 without having IgG4-associated cholangitis. Don't reflexively change the diagnosis based on IgG4 alone. Look at the whole picture:
- Markedly elevated IgG4 ( > 4× ULN) + autoimmune pancreatitis features + dense IgG4+ plasma cells on biopsy = IgG4-SC
- Mildly elevated IgG4 (1–2× ULN) + typical PSC cholangiogram + IBD = still PSC with incidentally elevated IgG4
The practical difference: IgG4-SC responds dramatically to corticosteroids; PSC does not.
| Marker | Role in PSC | Interpretation |
|---|---|---|
| CA 19-9 | Screening for cholangiocarcinoma; annual monitoring | CA 19-9 may or may not be elevated and is nonspecific [13]. Sensitivity ~60–70% for cholangiocarcinoma. Also elevated in benign cholestasis, pancreatitis, other GI malignancies. A level > 129 U/mL in PSC has ~80% sensitivity and ~98% specificity for cholangiocarcinoma. Lewis-antigen-negative individuals (~7% of population) cannot produce CA 19-9 |
| CEA | Adjunctive; less useful than CA 19-9 | CEA may be elevated in cholangiocarcinoma but neither sensitive nor specific [17]. Primarily a CRC marker |
| AFP | To exclude HCC | AFP differentiates intrahepatic cholangiocarcinoma from HCC [17]. Should be normal in PSC unless HCC has developed on cirrhotic background |
| Test | Purpose |
|---|---|
| CBC with differentials | Leukocytosis → suggests superimposed cholangitis. Thrombocytopaenia → suggests portal hypertension/hypersplenism or advanced cirrhosis. Check thrombocytopaenia when planning invasive procedures such as ERCP [17] |
| Clotting profile | Coagulopathy due to vitamin K deficiency from decreased absorption of fat-soluble vitamins due to obstructive jaundice [17][8] |
| RFT (Renal function) | Baseline before ERCP contrast; assess for hepatorenal syndrome in advanced disease |
| CRP / ESR | Inflammatory markers — elevated in acute cholangitis or disease flare |
| Blood culture | If febrile — blood culture is essential in suspected acute cholangitis [2] |
| Fat-soluble vitamin levels (A, D, E, K) | Chronic cholestasis → malabsorption of fat-soluble vitamins → monitor and replace |
| HBV / HCV serology | Exclude concurrent viral hepatitis as cause of abnormal LFTs |
B. Imaging Modalities
USG is typically the first imaging test obtained in a patient with cholestatic LFTs or jaundice. It is not diagnostic for PSC but provides critical screening information.
| Finding | Significance | Mechanism |
|---|---|---|
| Bile duct wall thickening | Suggestive of inflammatory biliary disease | Periductal inflammation and fibrosis → thickened duct wall [1] |
| Focal bile duct dilatation | Dilatation between strictured segments | Bile stasis proximal to strictures → segmental dilatation [1] |
| Gallbladder wall thickening and enlargement | May reflect PSC-associated gallbladder inflammation | PSC increases risk of gallbladder carcinoma; any gallbladder abnormality needs follow-up [1] |
| Presence of gallstones | Exclude choledocholithiasis as cause of cholestasis | Gallstones coexist in ~25% of PSC patients [1] |
| CBD diameter | Normal CBD < 8 mm (< 0.8 cm); intrahepatic ducts normally not visible ( < 2–3 mm). CBD > 0.8 cm is pathological. Intrahepatic duct normally not visible on USG [17] | If dilated → suggests obstruction; but in PSC, ductal calibre can vary due to alternating strictures and dilatation |
| Liver parenchyma | Heterogeneous echotexture in advanced disease; features of cirrhosis (irregular surface, caudate hypertrophy) | Progressive periportal fibrosis → cirrhosis |
| Splenomegaly | Suggests portal hypertension | Biliary cirrhosis → portal hypertension → splenic congestion |
Limitation: USG has limited sensitivity for detecting intrahepatic strictures and cannot characterise the full extent of biliary disease. It is a screening tool, not a diagnostic one for PSC. The next step is always MRCP.
MRCP is typically the 1st imaging modality due to non-invasiveness and comparable diagnostic accuracy to ERCP [1].
How MRCP works (from first principles): MRCP uses heavily T2-weighted MRI sequences. In T2-weighted imaging, stationary fluid (like bile in the biliary tree) appears bright white against a dark background. This creates a "cholangiogram" without injecting any contrast — the bile itself acts as the contrast agent. Non-contrast, T2-weighted imaging [18].
| Finding | Description | Clinical Significance |
|---|---|---|
| Multifocal strictures alternating with dilatation | The hallmark "beaded" appearance: short, annular strictures with intervening dilated segments | Characteristic multifocal strictures that alternate with dilation of intrahepatic or extrahepatic bile ducts resulting in "beaded" appearance of bile duct [1]. This is the diagnostic finding |
| Intrahepatic ± extrahepatic involvement | ~70% have both; ~25% intrahepatic only; ~5% extrahepatic only | Pattern helps classify the subtype and plan management |
| Pruned-tree appearance | Loss of peripheral intrahepatic duct branches | Advanced disease: progressive fibrosis has obliterated small ducts → the peripheral arborisation is lost, giving the appearance of a pruned tree |
| Diverticulum-like outpouchings | Small outpouchings from bile duct wall | Represent areas of duct wall weakening between segments of fibrosis |
| Dominant stricture | Stricture ≤ 1.5 mm in CBD or ≤ 1.0 mm in hepatic duct | Must be investigated to exclude superimposed cholangiocarcinoma — ERCP with brush cytology indicated |
| Gallbladder abnormalities | Wall thickening, polyps, mass | PSC patients need annual USG for gallbladder surveillance; polyps ≥ 8 mm warrant cholecystectomy [19] |
MRCP advantages over ERCP:
- Non-invasive (no sedation, no endoscope, no contrast injection)
- No risk of post-procedure pancreatitis or ascending cholangitis
- Does NOT require contrast injection into ductal system unlike in ERCP and PTC [17]
- Superior to ERCP for assessing tumour anatomy and resectability [17]
- Can visualise ducts above a complete obstruction (ERCP can only image ducts below the scope)
MRCP limitations:
- Cannot perform therapeutic intervention (stenting, dilatation, brush cytology)
- May miss very early/subtle PSC changes (sensitivity ~80–90% vs ERCP as reference)
- Spatial resolution slightly inferior to ERCP
ERCP is indicated in patients who are unable to undergo MRCP such as those with implanted metal devices or in patients with early PSC changes that may be missed by MRCP [1].
In the PSC context, ERCP has shifted from a primary diagnostic tool to a problem-solving and therapeutic tool.
| Indication in PSC | What It Offers |
|---|---|
| Dominant stricture evaluation | ERCP allows brush cytology ± FISH (fluorescence in situ hybridisation) of the strictured segment to exclude cholangiocarcinoma |
| Therapeutic dilatation | Balloon dilatation of dominant strictures that cause symptomatic cholestasis or recurrent cholangitis |
| Stent placement | Short-term stenting of dominant strictures (usually for 2–4 weeks) to relieve obstruction |
| Stone extraction | Removal of biliary sludge or stones that have formed within dilated/strictured ducts |
| Contraindication to MRCP | Patients with ferromagnetic implants, cochlear implants, or certain cardiac devices |
| Early PSC changes | Indicated in patients with early PSC changes that may be missed by MRCP [1] — when clinical suspicion is high but MRCP is normal/equivocal |
ERCP findings in PSC:
- Multiple short annular strictures with intervening normal or dilated segments
- "Band-like" strictures — short, sharp, concentric narrowings
- Diffuse involvement — both intrahepatic and extrahepatic tree
- Diverticulum-like outpouchings — representing ectasia between strictured segments
ERCP risks (important because PSC patients may need multiple ERCPs over their lifetime):
- Post-ERCP pancreatitis (~3–5%)
- Ascending cholangitis — involves injection of contrast into bile duct and hence risk for ascending cholangitis in cases of impaired biliary drainage [17]
- Perforation (~0.5%)
- Haemorrhage (from sphincterotomy)
- Bacteraemia (thus antibiotic prophylaxis required) [18]
ERCP in PSC — When and Why
ERCP is NOT first-line for PSC diagnosis anymore — MRCP has replaced it. Use ERCP when you need to:
- Sample a dominant stricture (brush cytology for cholangiocarcinoma)
- Treat a dominant stricture (balloon dilatation ± short-term stenting)
- Investigate when MRCP is equivocal or contraindicated
Always give prophylactic antibiotics before ERCP in PSC patients because their strictured, stagnant bile is a setup for post-procedural sepsis.
PTC is preferred to ERCP in stricture/obstruction at or above the level of confluence of hepatic ducts [18] — i.e., hilar-level disease where ERCP cannot access above the obstruction.
| Role in PSC | Details |
|---|---|
| Diagnostic | Visualisation of biliary tree above a complete hilar obstruction (where ERCP contrast cannot pass) |
| Therapeutic | Percutaneous transhepatic biliary drainage (PTBD) — inserting a catheter to decompress dilated intrahepatic ducts; placement of indwelling stents |
| Sampling | Brush cytology/biopsy of hilar strictures |
Complications: Bacteraemia (thus antibiotic prophylaxis required), haemobilia [18].
CT is not the primary diagnostic modality for PSC but plays important supporting roles:
| Role | Details |
|---|---|
| Exclude malignancy | Detect intrahepatic mass lesions (cholangiocarcinoma, HCC), lymphadenopathy, metastases |
| Assess liver morphology | Evaluate for cirrhosis (irregular surface, caudate lobe hypertrophy, segmental atrophy — particularly hypertrophy of caudate + left lateral segment with atrophy of right and left medial segments in advanced PSC) |
| Vascular assessment | Portal vein patency, hepatic artery involvement (relevant if transplant is being considered) |
| Exclude RPC | CT shows central dilated bile ducts with peripheral tapering, left lobe predilection, liver atrophy in RPC [6] |
| Role | Details |
|---|---|
| Non-invasive fibrosis assessment | Measures liver stiffness as a surrogate for fibrosis stage. MR elastography is more accurate than transient elastography in biliary diseases because cholestasis itself can falsely elevate liver stiffness |
| Prognostic value | Higher stiffness correlates with more advanced fibrosis and worse outcomes |
| Limitations | Periductal fibrosis in PSC creates heterogeneous stiffness; may overestimate fibrosis compared to parenchymal liver diseases |
C. Histological Examination (Liver Biopsy)
Percutaneous liver biopsy may support diagnosis of PSC but is rarely diagnostic and is not routinely recommended [1].
| Indication | Rationale |
|---|---|
| Suspected small-duct PSC | Normal MRCP/ERCP but clinical and biochemical features suggest PSC → biopsy is the only way to see changes in small ducts |
| Suspected PSC-AIH overlap | Need to demonstrate interface hepatitis + biliary changes; directs immunosuppressive therapy |
| Excluding other causes | Sarcoidosis (granulomas), amyloidosis, drug reaction |
| Staging fibrosis | When non-invasive methods are inconclusive; guides prognosis and transplant timing |
| Stage | Finding | What You See |
|---|---|---|
| Hallmark | Concentric periductal "onion-skin" fibrosis | Rings of collagen concentrically layered around medium-sized bile ducts; seen in only ~30–40% of biopsy specimens (because the patchy distribution means biopsy may miss it) |
| Stage 1 (Portal) | Portal hepatitis, portal oedema, bile duct proliferation | Inflammation limited to portal tracts |
| Stage 2 (Periportal) | Periportal fibrosis, periportal hepatitis | Fibrosis extends beyond portal tracts |
| Stage 3 (Septal) | Septal fibrosis, bridging necrosis | Fibrous septa connecting portal tracts |
| Stage 4 (Cirrhotic) | Biliary cirrhosis | Regenerative nodules, complete architectural distortion |
Why is biopsy rarely diagnostic? Because the hallmark onion-skin fibrosis is found in only ~30–40% of biopsy specimens due to sampling error — PSC is patchy and predominantly affects larger ducts that may not be captured in a needle biopsy of the liver parenchyma. This is why cholangiography (MRCP/ERCP) is superior to biopsy for diagnosing large-duct PSC.
This deserves its own section because it's frequently overlooked:
- All patients diagnosed with PSC should undergo colonoscopy with biopsies to screen for IBD, even if they have no GI symptoms [1].
- Why? Because ~60–80% of PSC patients have UC, and the colitis in PSC-IBD is often subclinical (pancolitis with rectal sparing and minimal symptoms).
- Primary sclerosing cholangitis → yearly surveillance colonoscopy [3] — if IBD is confirmed, annual colonoscopy is mandated from the time of PSC diagnosis because of the markedly elevated CRC risk.
- If no IBD is found on initial colonoscopy, repeat colonoscopy every 5 years (because IBD can develop later).
- Chronic cholestasis → vitamin D malabsorption → osteoporosis/osteomalacia
- DEXA scan at diagnosis and every 2–3 years to monitor bone mineral density
- Treat with calcium + vitamin D supplementation; bisphosphonates if T-score ≤ −2.5
| Category | Tests | Key Findings |
|---|---|---|
| Biochemistry | LFT, albumin, bilirubin, PT/INR | Cholestatic pattern: ALP > > ALT; fluctuating bilirubin |
| Serology | AMA, p-ANCA, ANA, SMA, IgG4, IgM, IgG | AMA negative, p-ANCA positive, IgG4 normal |
| Tumour markers | CA 19-9, CEA, AFP | Baseline for cholangiocarcinoma surveillance |
| Other bloods | CBC, CRP, RFT, clotting, fat-soluble vitamins, HBV/HCV serology | Exclude differentials; assess synthetic function |
| Imaging — Screening | USG abdomen | Duct wall thickening, focal dilatation, gallstones, GB abnormalities |
| Imaging — Diagnostic | MRCP (1st line) | Multifocal "beaded" strictures |
| Imaging — Therapeutic/Diagnostic | ERCP (if dominant stricture, MRCP contraindicated, or need for intervention) | Strictures + brush cytology ± FISH for malignancy |
| Imaging — Adjunctive | CT abdomen, PTC (if hilar obstruction) | Exclude malignancy; assess liver morphology |
| Histology | Liver biopsy (only if small-duct PSC or overlap suspected) | Onion-skin periductal fibrosis |
| Endoscopy | Colonoscopy with biopsies | Screen for IBD; annual surveillance if IBD confirmed |
| Bone health | DEXA scan, vitamin D level | Screen for osteoporosis |
High Yield Summary — Diagnosis of PSC
-
PSC diagnosis requires: Cholestatic biochemistry (ALP > 1.5× ULN for > 6 months) + characteristic cholangiographic findings (multifocal "beaded" strictures on MRCP) + exclusion of secondary causes.
-
MRCP is the first-line diagnostic imaging modality — non-invasive, no contrast injection, comparable accuracy to ERCP [1].
-
AMA is typically absent in PSC — its presence should prompt consideration of PBC or overlap syndrome [1].
-
Serum IgG4 must be checked to exclude IgG4-associated cholangitis (which responds to steroids) [1].
-
Liver biopsy is NOT routinely needed — reserved for small-duct PSC (normal cholangiogram) or suspected PSC-AIH overlap [1].
-
ERCP is now primarily therapeutic/problem-solving — for dominant stricture evaluation (brush cytology), balloon dilatation, and stenting. Not first-line diagnostic.
-
PTC is preferred over ERCP for hilar-level obstruction [18].
-
All PSC patients need colonoscopy to screen for IBD, regardless of GI symptoms. If IBD present → annual colonoscopy for CRC surveillance.
-
Tumour markers (CA 19-9, CEA) are baseline and for surveillance — neither sensitive nor specific alone.
-
Key biochemical pattern: ALP 3–10× ULN, ALT < 2× ULN, fluctuating bilirubin, AMA negative, p-ANCA positive.
Active Recall - PSC Diagnostic Criteria, Algorithm and Investigations
[1] Senior notes: felixlai.md (Primary Sclerosing Cholangitis section, felix:756–757) [2] Senior notes: maxim.md (Acute cholangitis section, maxim:288) [3] Lecture slides: Inflammatory bowel disease.pdf (p52, p56 — CRC surveillance in PSC) [6] Senior notes: maxim.md (Recurrent pyogenic cholangitis, maxim:290) [8] Senior notes: maxim.md (Obstructive jaundice section, maxim:251–252) [13] Lecture slides: WCS 064 - A large liver - by Prof R Poon [20191108].doc.pdf (p5 — Cholangiocarcinoma diagnosis) [16] Senior notes: felixlai.md (Primary biliary cholangitis, felix:760–761) [17] Senior notes: felixlai.md (Cholangiocarcinoma diagnosis, felix:780–782; MBO investigations, felix:723) [18] Senior notes: maxim.md (HBP investigations — MRCP, PTC, ERCP, maxim:250–251) [19] Senior notes: maxim.md (Gallbladder polyps management in PSC, maxim:292)
Management of Primary Sclerosing Cholangitis
Let me be upfront about this: PSC is one of the most frustrating diseases in hepatology to manage. Why? Because:
- There is no proven medical therapy that alters the natural history of the disease
- NONE of the following agents are proven to alter the natural history of the disorder — Glucocorticoid, Cyclosporine, Methotrexate, Azathioprine, Tacrolimus [1]
- UDCA is NOT generally recommended in PSC due to uncertain benefits [1]
- The only definitive treatment is liver transplantation for advanced disease [1]
So the management of PSC is fundamentally about: (a) managing symptoms, (b) treating complications as they arise, (c) surveillance for malignancy, and (d) knowing when to refer for transplantation. Think of it as chronic disease management with serial troubleshooting, not curative treatment.
A. Medical Management
Let's break down the name: "urso" = bear (Latin ursus), "deoxy" = oxygen removed, "cholic acid" = a bile acid. UDCA was originally isolated from bear bile — it is a hydrophilic bile acid that constitutes only ~3% of the human bile acid pool.
Mechanism of action (theoretical in PSC):
- Replaces toxic hydrophobic bile acids in the bile acid pool → protects cholangiocytes from bile acid–mediated injury
- Stimulates biliary secretion (choleresis) → improves bile flow
- Has anti-inflammatory and immunomodulatory properties (reduces HLA class I expression on hepatocytes)
- Stabilises the "bicarbonate umbrella" on cholangiocyte apical membranes
The evidence problem:
| Dose | Outcome | Status |
|---|---|---|
| Standard dose (13–15 mg/kg/day) | Improves liver biochemistry (ALP, bilirubin) but has NOT been shown to improve transplant-free survival, prevent progression to cirrhosis, or reduce cholangiocarcinoma risk in large RCTs | NOT generally recommended [1] |
| High dose (28–30 mg/kg/day) | Actually associated with worse outcomes — higher rates of serious adverse events (varices, death, need for transplant) in a landmark RCT (Lindor et al., Hepatology 2009) | Contraindicated |
UDCA in PSC — The Bottom Line
UDCA is NOT generally recommended in PSC due to uncertain benefits [1]. This is fundamentally different from PBC, where UDCA at 13–15 mg/kg/day is 1st line therapy and has proven survival benefit [20].
In PBC: UDCA works → proven to delay progression and improve survival. Continue indefinitely. In PSC: UDCA improves blood tests cosmetically but does NOT change outcomes. High-dose is harmful.
Some hepatologists still prescribe low-dose UDCA in PSC for symptomatic improvement of pruritus or biochemistry, but this is not guideline-recommended by AASLD (2010) or EASL (2022). It should not be presented as "treatment" in exams.
This seems counterintuitive for an immune-mediated disease, so let me explain why:
- PSC is driven primarily by innate immune mechanisms and fibrosis rather than classic adaptive autoimmunity
- The periductal fibrosis, once established, is self-perpetuating — suppressing the immune system doesn't reverse scar tissue
- The gut-liver axis (aberrant lymphocyte homing via MAdCAM-1) is not effectively targeted by conventional immunosuppressants
- Unlike AIH, where interface hepatitis responds to steroids, the biliary-targeted injury in PSC follows a different pathway
| Agent | Mechanism | Result in PSC |
|---|---|---|
| Glucocorticoids (Prednisolone) | Broad anti-inflammatory; suppresses T-cell activation | No benefit in PSC; significant side effects (osteoporosis, diabetes, weight gain). Exception: Used in PSC-AIH overlap where the AIH component responds |
| Azathioprine | Purine antimetabolite; inhibits lymphocyte proliferation | No benefit alone or combined with steroids in PSC |
| Methotrexate | Folate antagonist; suppresses T-cell-mediated inflammation | No benefit; risk of hepatotoxicity (can itself cause hepatic fibrosis) |
| Cyclosporine | Calcineurin inhibitor; blocks T-cell activation via IL-2 pathway | No benefit in RCTs |
| Tacrolimus | Calcineurin inhibitor (more potent than cyclosporine) | Improves biochemistry but no evidence of histological or clinical benefit |
| Mycophenolate mofetil | Inhibits purine synthesis in lymphocytes | No benefit in PSC |
NONE of the following agents are proven to alter the natural history of the disorder — Glucocorticoid, Cyclosporine, Methotrexate, Azathioprine, Tacrolimus [1].
The One Exception — PSC-AIH Overlap
PSC-AIH overlap syndrome (~5–10% of PSC patients) does respond to immunosuppression. If you identify interface hepatitis on biopsy with elevated IgG and positive ANA/SMA alongside typical PSC cholangiographic findings, treat the AIH component with:
- Prednisolone (induction) + Azathioprine (maintenance)
- Continue UDCA for the biliary component (though evidence is weak)
This is the only subset of "PSC" where immunosuppression is warranted.
While no agent has achieved regulatory approval specifically for PSC as of 2026, several are in advanced clinical trials and worth knowing:
| Agent | Mechanism | Status |
|---|---|---|
| Obeticholic acid (OCA) | FXR (farnesoid X receptor) agonist; modulates bile acid homeostasis | Phase 3 trial (AESOP) completed; shown to reduce ALP but liver-related clinical outcomes pending. Already approved for PBC |
| Nor-UDCA (norursodeoxycholic acid) | Side-chain-shortened UDCA analogue; undergoes cholehepatic shunting → induces bicarbonate-rich choleresis | Phase 3 (NorUDCA PSC trial); showed significant ALP reduction vs placebo. Most promising pipeline agent |
| Cilofexor | Non-steroidal FXR agonist | Phase 2 showed modest ALP reduction |
| Simtuzumab | Anti-LOXL2 antibody (targets cross-linking enzyme in fibrosis) | Failed Phase 2 — no efficacy |
| Vedolizumab | Anti-α4β7 integrin (blocks gut lymphocyte homing to gut; already approved for UC/CD) | Paradoxically, by blocking α4β7, it may reduce hepatic lymphocyte recruitment. Case series show variable results; trials ongoing |
| Vancomycin (oral) | Alters gut microbiome; reduces secondary bile acid production | Small studies in paediatric PSC show dramatic ALP improvement. Adult data less convincing. Not guideline-recommended |
B. Endoscopic Management — Dominant Stricture Management
This is where the real procedural action happens in PSC management. Patients with dominant stricture or cholangitis should undergo endoscopic therapy to dilate or stent the stricture to relief jaundice and pruritus [1].
A dominant stricture is a stenosis with luminal diameter ≤ 1.5 mm in the CBD or ≤ 1.0 mm in a hepatic duct. It occurs in ~50% of PSC patients during their disease course and represents a critical management inflection point because:
- It causes clinically significant cholestasis (worsening jaundice, pruritus)
- It predisposes to recurrent bacterial cholangitis
- It must be investigated to exclude cholangiocarcinoma (10–20% lifetime risk)
| Procedure | Details | Why |
|---|---|---|
| Brush cytology | Sweep a cytology brush across the strictured segment during ERCP; cells examined for dysplasia/malignancy | Cholangiocarcinoma complicating PSC can be very difficult to distinguish from benign stricture. Brush cytology has ~40–60% sensitivity; adding FISH (polysomy detection) improves sensitivity to ~60–70% |
| Balloon dilatation | Graduated dilation of the stricture using an inflatable balloon passed through the endoscope | First-line treatment for dominant strictures; avoids the complications of indwelling stents. Improves bile flow, relieves jaundice and pruritus |
| Short-term plastic stent | Placed only if dilatation alone fails to achieve adequate drainage; typically left for 2–4 weeks only | Long-term stenting is avoided in PSC because indwelling stents promote bacterial biofilm formation → recurrent cholangitis → accelerated stricture progression. Biliary stent in-situ serves as nidus for infection [2] |
Stenting in PSC — Less Is More
Unlike malignant biliary obstruction where permanent self-expanding metallic stents (SEMS) are used, PSC strictures should be managed with balloon dilatation alone whenever possible. If a stent is needed, use a short-term plastic stent (2–4 weeks) and schedule removal. Long-term stenting in PSC leads to:
- Stent occlusion → cholangitis
- Biofilm formation → recurrent infections
- Stricture worsening proximal and distal to stent
This is an important distinction from malignant biliary obstruction management where self-expandable metallic stents have longer patency [20].
PTC is preferred to ERCP in stricture/obstruction at or above the level of confluence of hepatic ducts [18] — i.e., when the dominant stricture is at the hilum and ERCP cannot access above it.
| Indication | Details |
|---|---|
| Failed ERCP access | Cannot cannulate past hilar stricture |
| Bilateral intrahepatic strictures | Need to drain both systems separately |
| Alternative drainage route | When endoscopic approach is contraindicated (e.g., altered anatomy — Billroth II gastrectomy, Roux-en-Y [21]) |
PSC patients are prone to recurrent bacterial cholangitis because strictured, stagnant bile is an excellent culture medium. The management follows the same principles as acute cholangitis from any cause — RAD: Resuscitation, Antibiotics, Drainage [2].
| Step | Action | Details |
|---|---|---|
| Resuscitation | NPO, IV fluids, monitor vitals and I/O [2] | Sepsis protocol; lactate, blood cultures before antibiotics |
| Antibiotics | IV Augmentin (mild) or IV Tazocin (severe) × 7 days [2] | Cover Gram-negatives (E. coli, Klebsiella) and anaerobes. Pathogens: GNR > Enterococcus; Pseudomonas if stent present [2] |
| Drainage | Urgent if Reynolds pentad or not responding to antibiotics for 24 hours [2] | ERCP with aspiration of pus/bile → balloon dilatation of causative stricture ± temporary stent. If ERCP fails → PTBD |
Management of cholangitis: Resuscitation → Treat sepsis with intravenous antibiotic → Decompression of biliary system (Endoscopic vs percutaneous) → Definitive management [22].
Key point for PSC-specific cholangitis: The "definitive management" step differs from stone-related cholangitis. In choledocholithiasis, you remove the stone. In PSC, you dilate the stricture — but the underlying disease persists, so cholangitis tends to recur. Prophylactic antibiotics (e.g., ciprofloxacin) may be considered for patients with frequent episodes.
D. Management of Symptoms
Pruritus in cholestasis is one of the most debilitating symptoms and the most common reason patients seek help. The itch is not caused by bile salts directly depositing in skin (an old theory) but by autotaxin-generated lysophosphatidic acid (LPA) acting on neural itch pathways.
| Step | Agent | Mechanism | Notes |
|---|---|---|---|
| 1st line | Cholestyramine (4–16 g/day) | Bile acid sequestrant (anion-exchange resin); binds bile salts in gut lumen → prevents enterohepatic recirculation → reduces circulating pruritogens | Take 2–4 hours apart from other medications (including UDCA) because it binds other drugs. Unpalatable taste; GI side effects (constipation, bloating) |
| 2nd line | Rifampicin (150–300 mg BD) | Induces hepatic microsomal enzymes (CYP3A4, CYP2C9) → enhances metabolism and biliary excretion of pruritogens; also has direct anti-inflammatory effects | Monitor LFTs — can cause drug-induced hepatitis (~5–12%); check LFTs at 2 weeks and monthly for 3 months. Colours urine/tears orange-red |
| 3rd line | Naltrexone (25–50 mg/day) | Opioid receptor antagonist; cholestatic pruritus is partly mediated by endogenous opioids (increased opioidergic tone in cholestasis) | Start at low dose (12.5 mg) to avoid opioid withdrawal-like reaction (even in opioid-naive patients). Not a good choice if patient requires opioid analgesia |
| 4th line | Sertraline (75–100 mg/day) | SSRI; mechanism in pruritus unclear but may modulate central itch processing via serotonergic pathways | Better tolerated than naltrexone; useful if concomitant depression |
| Refractory | Plasmapheresis / albumin dialysis (MARS) | Physically removes circulating pruritogens from blood | Temporary measure; used as bridge to liver transplantation |
| Definitive | Liver transplantation | Removes the diseased biliary tree; eliminates the source of cholestasis | The only treatment that definitively cures pruritus in PSC |
Mnemonic for pruritus stepladder: Come Running Now Sir → Cholestyramine → Rifampicin → Naltrexone → Sertraline
- Most difficult symptom to treat — no specific effective therapy
- Exclude and treat contributing factors: anaemia, hypothyroidism, depression, sleep disruption from pruritus
- General measures: exercise, sleep hygiene, caffeine management
- Modafinil has been tried anecdotally but not evidence-based
| Vitamin | Deficiency Consequence | Replacement |
|---|---|---|
| Vitamin A | Night blindness, dry eyes | Oral vitamin A 10,000–25,000 IU/day |
| Vitamin D | Osteoporosis, osteomalacia; hepatic osteodystrophy [20] | Oral cholecalciferol 1,000–4,000 IU/day; calcium supplementation; check 25-OH-vitamin D levels |
| Vitamin E | Peripheral neuropathy, ataxia | Oral vitamin E 400–800 IU/day |
| Vitamin K | Coagulopathy (prolonged PT/INR); vitamin K deficiency leading to decreased absorption of fat-soluble vitamins due to obstructive jaundice [8] | Oral phytomenadione 10 mg/day; IV if not absorbed orally or if urgent (pre-procedure) |
- Symptomatic steatorrhoea due to bile acid insufficiency can be partially corrected by restricting dietary fat [20]
- Medium-chain triglycerides (MCTs) do not require bile acids for absorption — they are absorbed by passive diffusion directly into portal circulation without requiring micellar formation [20]
- Pancreatic enzyme supplementation if concurrent pancreatic insufficiency
- Osteoporosis is more common than osteomalacia in PSC
- DEXA scan at diagnosis → repeat every 2–3 years
- Management: Calcium + Vitamin D supplementation → bisphosphonates (alendronate/risedronate) if T-score ≤ −2.5
- Weight-bearing exercise; fall prevention
E. Liver Transplantation — The Definitive Treatment
Liver transplantation is the treatment of choice for patients with advanced liver disease due to PSC [1].
| Indication | Details |
|---|---|
| Decompensated cirrhosis | Signs and symptoms of hepatic decompensation: abdominal distension from ascites, confusion from hepatic encephalopathy, haematemesis from oesophageal variceal bleeding [1] |
| MELD score ≥ 15 | MELD score incorporates creatinine (hepatorenal syndrome), bilirubin, INR ± Na [20]; score > 15 indicates transplant benefit exceeds risk of surgery |
| Recurrent bacterial cholangitis | Uncontrollable despite endoscopic management; significantly impairs quality of life |
| Intractable pruritus | Refractory to all medical therapy; can be severely debilitating |
| Cholangiocarcinoma (selected cases) | Perihilar cholangiocarcinoma arising in PSC — selected patients may undergo neoadjuvant chemoradiation followed by liver transplantation (the "Mayo Protocol"). This is one of the few accepted transplant indications for cholangiocarcinoma |
| Hepatocellular carcinoma | Within transplant criteria (Milan/UCSF criteria) if cirrhosis has developed |
- 5-year survival: ~85% (excellent — among the best outcomes for any transplant indication)
- 10-year survival: ~70%
- Recurrent PSC post-transplant: Occurs in ~20–25% of cases; the disease can recur in the allograft, typically 3–5 years post-transplant. This confirms the immunological basis of the disease (it follows the patient, not the liver)
| Absolute | Relative |
|---|---|
| Active uncontrolled infection [20] | Advanced age ( > 65–70) |
| Active alcohol/substance abuse [20] | Severe cardiopulmonary disease |
| Unresectable extrahepatic malignancy | Morbid obesity (BMI > 40) |
| Irreversible multi-organ failure | Non-compliance with medical follow-up |
| Advanced cholangiocarcinoma (not meeting Mayo Protocol criteria) | HIV (well-controlled HIV is no longer an absolute contraindication) |
| Consideration | Details |
|---|---|
| Cholangiocarcinoma screening | Must actively exclude CCA before listing — annual MRCP + CA 19-9; ERCP with brush cytology if any dominant stricture |
| CRC screening | Active CRC or high-grade dysplasia may affect transplant eligibility |
| IBD management | IBD may flare or change course post-transplant (especially with immunosuppression); patients who have had colectomy pre-transplant may have pouch complications post-transplant |
| Bone health | Immunosuppression (especially corticosteroids) post-transplant accelerates osteoporosis in patients already at risk |
Historically, biliary reconstructive surgery (e.g., hepaticojejunostomy) was attempted for PSC but is now largely abandoned because:
- It makes subsequent liver transplantation technically much more difficult (adhesions, altered anatomy)
- It does not alter disease progression
- It carries significant operative morbidity (bile leaks, stricture recurrence, cholangitis)
The only non-transplant surgical indication in PSC is cholecystectomy for:
- Gallbladder mass or polyp ≥ 8 mm — adenomatous polyps ≥ 1cm (or 8 mm if underlying PSC) [19]
- Gallbladder carcinoma
- Symptomatic cholelithiasis
This is not optional — it is core management. PSC patients carry increased risk of cholangiocarcinoma, CRC, gallbladder carcinoma, and HCC.
| Cancer | Surveillance | Frequency | Rationale |
|---|---|---|---|
| Cholangiocarcinoma | MRCP + CA 19-9 | Annual | 10–20% lifetime risk; strong association with cholangiocarcinoma especially perihilar disease [9]. Any new dominant stricture → ERCP with brush cytology ± FISH |
| Colorectal cancer | Colonoscopy with chromoendoscopy and biopsies | Yearly if concurrent IBD [3] | PSC is a risk factor for IBD-associated colorectal neoplasia [3]. CRC risk 4–5× higher than UC alone. Primary sclerosing cholangitis: yearly surveillance colonoscopy [3] |
| Gallbladder carcinoma | USG abdomen | Annual | Cholecystectomy if mass or polyp ≥ 8 mm |
| Hepatocellular carcinoma | USG + AFP (if cirrhosis established) | Every 6 months | Standard HCC surveillance for cirrhosis from any cause |
The IBD in PSC-UC has unique features and requires specific attention:
- Colitis may be quiescent despite significant liver disease — don't be falsely reassured
- 5-ASA (mesalazine) is the mainstay for mild-to-moderate UC; some evidence suggests it may also be chemopreventive for CRC in PSC-UC
- Immunosuppressants (azathioprine, biologics) for moderate-to-severe IBD follow standard IBD protocols
- Elective surgery for debilitating extra-intestinal manifestations, except those independent of colitis activity — sacroiliitis, hepatobiliary complications [23] — meaning PSC itself is NOT an indication for colectomy (it doesn't improve after colectomy; it can even present after colectomy)
- Post-transplant: IBD can worsen (immunosuppressive regimens differ from IBD-specific ones); close monitoring needed
| Clinical Scenario | Management |
|---|---|
| Asymptomatic PSC | Surveillance only (MRCP, colonoscopy, LFTs, vitamins, bone health) |
| Pruritus | Cholestyramine → Rifampicin → Naltrexone → Sertraline → Plasmapheresis → Transplant |
| Dominant stricture | ERCP: brush cytology (exclude CCA) + balloon dilatation ± short-term plastic stent |
| Acute cholangitis | RAD: Resuscitation → Antibiotics → Drainage [2] |
| Fat-soluble vitamin deficiency | Oral vitamin A, D, E, K supplementation |
| Metabolic bone disease | Calcium + Vitamin D; bisphosphonates if osteoporosis |
| Steatorrhoea | Low-fat diet + MCT supplementation |
| PSC-AIH overlap | Prednisolone + Azathioprine (the only subset where immunosuppression works) |
| Advanced cirrhosis / decompensation | Liver transplantation |
| Cholangiocarcinoma in PSC | Selected patients: neoadjuvant chemoradiation + liver transplant (Mayo Protocol); otherwise palliative stenting |
| Concurrent IBD | Standard UC/CD management; annual colonoscopy; 5-ASA as CRC chemoprevention |
| Gallbladder polyp ≥ 8 mm | Cholecystectomy |
High Yield Summary — Management of PSC
-
No proven medical therapy alters the natural history of PSC. UDCA is NOT generally recommended; immunosuppressants (steroids, azathioprine, cyclosporine, methotrexate, tacrolimus) have all failed [1].
-
Dominant strictures are managed with ERCP balloon dilatation ± short-term plastic stent. Always perform brush cytology to exclude cholangiocarcinoma. Avoid long-term stenting.
-
Acute cholangitis follows RAD: Resuscitation → Antibiotics → Drainage [2]. Antibiotics: IV Augmentin (mild) or IV Tazocin (severe) [2].
-
Pruritus stepwise: Cholestyramine → Rifampicin → Naltrexone → Sertraline. Mnemonic: "Come Running Now Sir."
-
Liver transplantation is the treatment of choice for advanced liver disease [1]. 5-year survival ~85%. PSC recurs in ~20% of allografts.
-
PSC-AIH overlap is the ONLY PSC variant that responds to immunosuppression (prednisolone + azathioprine).
-
Cancer surveillance is mandatory: Annual MRCP + CA 19-9 (CCA), yearly colonoscopy if IBD [3], annual USG (gallbladder), 6-monthly USG + AFP if cirrhotic (HCC).
-
Fat-soluble vitamins (A, D, E, K) must be supplemented. Metabolic bone disease needs DEXA and treatment.
-
Cholecystectomy for GB polyps ≥ 8 mm in PSC (lower threshold than general population's 10 mm) [19].
-
Biliary reconstructive surgery is largely abandoned — it makes subsequent transplantation harder without altering disease progression.
Active Recall - PSC Management
References
[1] Senior notes: felixlai.md (PSC Treatment section, felix:758) [2] Senior notes: maxim.md (Acute cholangitis management — RAD, maxim:288–289) [3] Lecture slides: Inflammatory bowel disease.pdf (p52, p56 — CRC surveillance in PSC; yearly colonoscopy) [8] Senior notes: maxim.md (Obstructive jaundice — biliary obstruction consequences, maxim:251) [9] Senior notes: felixlai.md (Cholangiocarcinoma risk factors — PSC association, felix:778) [18] Senior notes: maxim.md (HBP investigations — PTC preferred for hilar obstruction, maxim:250–251) [19] Senior notes: maxim.md (Gallbladder polyps management — 8 mm threshold in PSC, maxim:292) [20] Senior notes: felixlai.md (PBC treatment — UDCA, vitamin supplementation, liver transplant, felix:763; maxim liver transplant criteria, maxim:268) [21] Lecture slides: GC 200. RUQ pain, jaundice and fever Cholecytitis and cholangitis Imaging of GI system.pdf (p14 — ERCP contraindications) [22] Lecture slides: Malignant biliary obstruction.pdf (p15, p17 — Management of cholangitis and biliary obstruction) [23] Senior notes: maxim.md (IBD surgical indications — EIM independent of colitis, maxim:190)
Complications of Primary Sclerosing Cholangitis
PSC itself progresses silently in many patients for years. The morbidity and mortality come overwhelmingly from the complications of the disease rather than the primary pathology per se. Think of PSC as a slow-burning fire in the biliary tree: the strictures form quietly, but the consequences — cholestasis, cirrhosis, infection, and cancer — are what kill or debilitate patients.
Let's organise the complications into a logical framework that follows the pathophysiological cascade:
I. Complications of Cholestasis
These complications arise because bile cannot flow properly through the strictured biliary tree. The retained bile and its constituents cause systemic damage.
Steatorrhoea and vitamin deficiency result from decreased biliary secretion of bile acids [1][24].
From first principles: Bile salts are essential for the emulsification and absorption of dietary fats. They form mixed micelles with fatty acids and monoglycerides in the duodenal lumen, which are then absorbed across the enterocyte brush border. When bile salt delivery to the duodenum is reduced (because strictures impair bile flow), fat remains undigested in the gut lumen → steatorrhoea (greasy, foul-smelling, floating stools that are pale because of absent stercobilin).
- Fat malabsorption leads to caloric loss and weight loss
- The degree of steatorrhoea correlates with the severity of cholestasis
Leads to decreased absorption of fat-soluble vitamins A, D, E, K. Vitamin A and D deficiency are more common requiring supplementation [24].
Fat-soluble vitamins (mnemonic: ADEK) require bile salt-mediated micellar solubilisation for intestinal absorption. When bile salt delivery fails:
| Vitamin | Consequence of Deficiency | Pathophysiological Mechanism |
|---|---|---|
| Vitamin A | Night blindness (nyctalopia), xerophthalmia, dry skin | Vitamin A (retinol) is essential for rhodopsin synthesis in retinal rods; without adequate bile salts, retinol cannot be absorbed from the gut |
| Vitamin D | Osteomalacia, osteoporosis (see hepatic osteodystrophy below), hypocalcaemia | Cholecalciferol (vitamin D3) requires bile salts for absorption. Deficiency → impaired intestinal calcium absorption → secondary hyperparathyroidism → bone resorption. The liver also hydroxylates vitamin D to 25-OH-vitamin D (calcidiol) — hepatic dysfunction further impairs this step |
| Vitamin E | Peripheral neuropathy, ataxia (spinocerebellar degeneration), haemolytic anaemia | Vitamin E (alpha-tocopherol) is a fat-soluble antioxidant; its deficiency leads to oxidative damage to neuronal membranes and red blood cells |
| Vitamin K | Coagulopathy (prolonged PT/INR, easy bruising, bleeding) | Vitamin K is a cofactor for hepatic gamma-carboxylation of clotting factors II, VII, IX, X and proteins C and S. Vitamin K deficiency leading to decreased absorption of fat-soluble vitamins due to obstructive jaundice [8] |
Clinical Pearl — Is It Malabsorption or Synthetic Failure?
When you see a prolonged PT/INR in a PSC patient, always determine whether it's vitamin K malabsorption (reversible) or hepatic synthetic failure (irreversible without transplant):
- Give IV vitamin K 10 mg and recheck INR in 24–48 hours
- If INR corrects → malabsorption (bile salt deficiency)
- If INR does NOT correct → liver synthetic failure (the hepatocytes are too damaged to make clotting factors even with adequate substrate)
This distinction has major implications for prognosis and transplant timing.
Metabolic bone disease includes osteopenia and osteoporosis or rarely osteomalacia. Characteristic bone disorder which reflects the inhibitory effect of a retained toxin on the osteoblast [24].
This is a specific and important complication of chronic cholestatic liver disease (both PSC and PBC):
- Osteoporosis (reduced bone density, normal mineralisation) is more common than osteomalacia in PSC
- Mechanism: retained bile constituents (e.g., bilirubin, lithocholic acid) directly inhibit osteoblast function → reduced bone formation. Additionally, vitamin D deficiency impairs calcium absorption → secondary hyperparathyroidism → bone resorption
- Osteomalacia (defective mineralisation of osteoid) is less common
- Mechanism: severe vitamin D deficiency → insufficient calcium and phosphate incorporation into bone matrix
- Clinical significance: Vertebral compression fractures, pathological fractures, chronic back pain
- Management: DEXA scan at diagnosis and every 2–3 years; calcium + vitamin D supplementation; bisphosphonates if T-score ≤ −2.5; weight-bearing exercise
Already discussed in the management section, but worth listing as a complication because it can be severely debilitating:
- Chronic pruritus → excoriations → skin infections → sleep deprivation → depression → markedly impaired quality of life
- Can be the primary reason for liver transplant referral even in the absence of advanced cirrhosis
- Mechanism: autotaxin-generated lysophosphatidic acid (LPA) rather than bile salt deposition in skin (old theory)
II. Complications of Biliary Strictures
The strictures are the defining anatomical lesion of PSC, and they generate their own cascade of problems.
Up to 60% of patients may develop a dominant stricture in intrahepatic or extrahepatic biliary tree [24].
A dominant stricture is defined as a luminal diameter ≤ 1.5 mm in the CBD or ≤ 1.0 mm in a hepatic duct. Why does this matter?
- Causes acute worsening of jaundice (increased bilirubin due to near-complete obstruction)
- Predisposes to recurrent bacterial cholangitis (bile stasis → bacterial overgrowth)
- Must be investigated to exclude cholangiocarcinoma — any new dominant stricture requires ERCP with brush cytology ± FISH
- Management: ERCP balloon dilatation ± short-term plastic stent
Choledocholithiasis and cholelithiasis due to cholesterol or pigment stones [24].
Why do PSC patients develop gallstones?
- Bile stasis → supersaturation of bile with cholesterol → cholesterol stone nucleation
- Altered bile composition (reduced bile salt:cholesterol ratio) → lithogenic bile
- Pigment stones can also form from bilirubin precipitation in the setting of chronic biliary inflammation
- Stones can form within the gallbladder (cholelithiasis) or within the bile ducts themselves (choledocholithiasis)
- Bilirubin may fluctuate substantially, possibly indicating transient blockage of strictured bile ducts by biliary sludge or small stones [1]
Cholangitis develops spontaneously in patients with bile duct stones or obstructing strictures or in patients after undergoing endoscopic or surgical manipulation [24].
From first principles: Normal bile is sterile. The sphincter of Oddi acts as a barrier preventing duodenal bacteria from ascending into the biliary tree. In PSC:
- Strictures cause bile stasis → stagnant bile is an excellent culture medium
- Endoscopic interventions (ERCP, stenting) disrupt the sphincter barrier → bacterial access
- Biliary stent in-situ serves as a nidus for infection [2]
- Pathogens: GNR (E. coli, Klebsiella) > Enterococcus; Pseudomonas if stent present [2]
Clinical presentation:
- Charcot's triad (50–70%): Fever, RUQ pain, jaundice [2]
- Reynolds pentad ( < 10%): Charcot's triad + shock + altered mental state [2] — this represents suppurative cholangitis with sepsis, a surgical emergency
Why is recurrent cholangitis so dangerous in PSC?
- Each episode causes further inflammation → additional scarring → worsening strictures → more stasis → more cholangitis → a vicious cycle
- Biliary sepsis with endotoxaemia, impaired reticuloendothelial function, and impaired cell-mediated immunity [8]
- Can precipitate acute hepatic decompensation
III. Complications of Cirrhosis and Portal Hypertension
As PSC progresses, periductal fibrosis extends into the parenchyma → bridging fibrosis → regenerative nodules → biliary cirrhosis. Once cirrhosis is established, PSC patients develop the same complications as any cirrhotic patient:
Liver cirrhosis is characterised by bridging fibrosis, distortion of hepatic architecture and formation of regenerative nodules [25].
| Complication | Pathophysiological Mechanism | Clinical Manifestation |
|---|---|---|
| Ascites | Sinusoidal portal hypertension → increased hydrostatic pressure in splanchnic capillaries + hypoalbuminaemia (reduced oncotic pressure) + splanchnic vasodilation → activation of RAAS → sodium and water retention → transudative ascites | Abdominal distension from ascites [1] |
| Oesophageal variceal bleeding | Portal hypertension → blood diverts through portosystemic collaterals → oesophageal and gastric submucosal veins dilate → varices → rupture when wall tension exceeds threshold (Laplace's law) | Haematemesis from oesophageal variceal bleeding [1] — a life-threatening emergency requiring urgent endoscopic band ligation |
| Hepatic encephalopathy | Portosystemic shunting → ammonia and other neurotoxins bypass hepatic detoxification → cross blood-brain barrier → astrocyte swelling (via glutamine synthesis) → cerebral oedema and impaired neurotransmission | Confusion from hepatic encephalopathy [1]. Can be precipitated by infection, GI bleeding, constipation, protein load, medications (sedatives, diuretics causing hyponatraemia/hypokalaemia) |
| Splenomegaly / Hypersplenism | Splenic congestion from portal hypertension → splenomegaly → increased sequestration and destruction of blood cells | Thrombocytopaenia, leukopenia, anaemia |
| Hepatorenal syndrome (HRS) | Splanchnic vasodilation → decreased effective arterial blood volume → renal vasoconstriction → progressive renal failure with avid sodium retention | Rising creatinine with no structural renal disease; type 1 HRS is rapidly progressive; type 2 is indolent |
Signs and symptoms of hepatic decompensation: abdominal distension from ascites, confusion from hepatic encephalopathy, haematemesis from oesophageal variceal bleeding [1].
Risk factors for decompensation of cirrhosis include bleeding, dehydration, infection, obesity, alcoholism, and medications [25].
Patients with PSC and cirrhosis are at increased risk of HCC [1][24].
- HCC develops on the background of cirrhosis from any cause — PSC is no exception
- Any cause of cirrhosis — infection (HBV, HCV), metabolic (ALD, NAFLD, Wilson's disease), immune (PBC, PSC) — can lead to HCC [11][26]
- However, the HCC risk in PSC-cirrhosis is lower than in HBV/HCV-related cirrhosis
- Surveillance: USG + AFP every 6 months once cirrhosis is established (standard protocol)
IV. Malignant Complications — The Cancers of PSC
This is arguably the most important section on complications because malignancy is the leading cause of death in PSC patients.
Strong association with cholangiocarcinoma especially perihilar disease [9].
Lifetime risk: 10–20% (some studies report up to 25%). This makes PSC the single strongest risk factor for cholangiocarcinoma worldwide.
Why does chronic biliary inflammation lead to cholangiocarcinoma?
- Chronic inflammation → repeated cycles of cholangiocyte injury and regeneration → accumulation of genetic mutations (similar to the inflammation → dysplasia → carcinoma sequence seen in UC-CRC)
- Bile stasis → prolonged exposure of cholangiocytes to toxic bile constituents → DNA damage
- Cholangiocarcinoma is characterised by slow growth, high rate of local invasion, mucin production and tendency to invade perineural sheath and spread along nerves [9]
- Association with ulcerative colitis (common in Westerners) and recurrent pyogenic cholangitis (common in Orientals) [13]
Key clinical features in PSC-associated CCA:
- Often occurs early in the disease course — ~50% of CCAs in PSC are diagnosed within the first 1–2 years of PSC diagnosis (sometimes simultaneously)
- Mostly occurs in patients > 50 years [13], but PSC-associated CCA can present earlier
- Typically perihilar (Klatskin tumour) — obstruction to just left or right hepatic duct alone will not cause obstructive jaundice [20]; obstruction at the bifurcation blocks both systems
- Presents as a new dominant stricture with rapidly progressive jaundice, weight loss, and rising CA 19-9
Surveillance and detection:
- Annual MRCP + serum CA 19-9
- Any new dominant stricture → ERCP with brush cytology ± FISH
- Tumour markers: CEA, CA 19-9 (may or may not be elevated, nonspecific) [13]
- FNAC or Trucut biopsy ONLY for unresectable cases [13]
Prognosis: Dismal. PSC-associated CCA has a worse prognosis than sporadic CCA. Most are unresectable at diagnosis. Hepatic resection is the treatment of choice (resectability rate about 20%) [13]. For selected patients with perihilar CCA arising in PSC, the Mayo Protocol (neoadjuvant chemoradiation + liver transplantation) offers 5-year survival of ~60–70%.
Cholangiocarcinoma — The Deadliest Complication
Cholangiocarcinoma is the leading cause of mortality in PSC patients and the most feared complication. Key exam points:
- Lifetime risk 10–20%
- ~50% diagnosed within 1–2 years of PSC diagnosis
- Typically perihilar
- Any new dominant stricture = CCA until proven otherwise
- Brush cytology with FISH on ERCP for diagnosis
- CA 19-9 > 129 U/mL has ~80% sensitivity for CCA in PSC
- PSC is a risk factor for IBD-associated colorectal neoplasia [3] — don't confuse CCA screening with CRC screening; they are separate surveillance programmes
Gallbladder cancer is an under-appreciated complication of PSC [24].
- PSC patients have a higher prevalence of gallbladder mass lesions — both benign (polyps, adenomyomatosis) and malignant
- Primary sclerosing cholangitis is a risk factor for gallbladder carcinoma [10][19]
- The threshold for cholecystectomy in PSC patients is lower: adenomatous polyps ≥ 1 cm (or 8 mm if underlying PSC) [19] — compared to 10 mm in the general population
- Surveillance: Annual USG abdomen to monitor gallbladder
- Any gallbladder mass lesion in a PSC patient should prompt cholecystectomy regardless of size
This is a complication of the PSC-IBD association rather than PSC directly, but it is one of the most clinically significant:
PSC is a patient-specific risk factor for IBD-associated colorectal neoplasia [3].
Why does PSC increase CRC risk above and beyond UC alone?
- The prevailing hypothesis: altered bile acid metabolism in PSC → increased concentration of secondary bile acids (deoxycholic acid) in the colon → direct mitogenic and DNA-damaging effects on colonic epithelium → accelerated dysplasia-carcinoma sequence
- PSC-UC patients have a 4–5× higher CRC risk than UC patients without PSC
- The colitis in PSC-UC is often pancolitis (extensive involvement), which itself is a CRC risk factor
Surveillance: Primary sclerosing cholangitis: yearly surveillance colonoscopy [3]. This is more frequent than standard IBD surveillance:
| Population | Surveillance Interval |
|---|---|
| PSC with IBD | Yearly colonoscopy from time of PSC diagnosis [3] |
| UC/CD without PSC | Started at a maximum 8 years after UC or Crohn's colitis; then every 1–3 years depending on risk [3] |
| Ulcerative proctitis | Not considered at increased risk [3] |
Ideally, surveillance colonoscopy should be performed when the disease is in remission [3].
- UDCA and 5-ASA (mesalazine) may have chemopreventive effects against CRC in PSC-UC, though evidence is not definitive
- If high-grade dysplasia or CRC is found → colectomy (total proctocolectomy with ileal pouch-anal anastomosis for UC; segmental resection may be considered in CD)
PSC doesn't just coexist with IBD — it modifies the behaviour of IBD and vice versa:
| Aspect | Details |
|---|---|
| IBD behaviour in PSC | Tends to be pancolitis with rectal sparing, backwash ileitis, and milder symptoms — but paradoxically higher CRC risk |
| PSC post-colectomy | PSC can develop, progress, or even present for the first time after total colectomy — proving that the gut-liver axis aberration is self-sustaining once established |
| Pouchitis | PSC-UC patients who undergo ileal pouch-anal anastomosis (IPAA) have higher rates of pouchitis (inflammation of the ileal pouch) than UC patients without PSC |
| IBD post-transplant | IBD may flare after liver transplantation due to changes in immunosuppressive regimens; new-onset IBD can also occur |
Even after definitive treatment (transplantation), PSC has a significant recurrence rate:
- Recurrent PSC in the allograft: ~20–25% at 5–10 years post-transplant
- Manifests as new biliary strictures in the transplanted liver with cholangiographic features identical to original PSC
- Must be distinguished from other causes of biliary strictures post-transplant: hepatic artery thrombosis (ischaemic cholangiopathy), chronic ductopenic rejection, ABO-incompatible graft
- Recurrence is more common in patients with concurrent IBD (supporting the gut-liver axis hypothesis)
- Recurrent PSC can lead to graft loss requiring re-transplantation
| Category | Specific Complications |
|---|---|
| Cholestasis-related | Steatorrhoea, fat-soluble vitamin deficiency (A, D, E, K), hepatic osteodystrophy, pruritus |
| Stricture-related | Dominant strictures (~60%) [24], choledocholithiasis/cholelithiasis, recurrent bacterial cholangitis |
| Cirrhosis-related | Ascites, hepatic encephalopathy, variceal bleeding [1], hepatorenal syndrome, spontaneous bacterial peritonitis, HCC |
| Malignancy | Cholangiocarcinoma (10–20% lifetime) [9], gallbladder carcinoma [24], CRC (via IBD) [3], HCC (via cirrhosis) |
| IBD-related | CRC, pouchitis post-IPAA, IBD flare post-transplant |
| Post-transplant | Recurrent PSC in allograft (~20–25%), rejection, vascular complications |
High Yield Summary — Complications of PSC
-
Cholestasis complications: Steatorrhoea, fat-soluble vitamin deficiency (A, D, E, K — mnemonic: ADEK), hepatic osteodystrophy (osteoporosis > osteomalacia), pruritus.
-
Dominant strictures develop in up to 60% of patients [24] — must always be investigated with ERCP brush cytology to exclude cholangiocarcinoma.
-
Recurrent bacterial cholangitis: Driven by bile stasis + strictures ± stent-related biofilm. Charcot's triad (fever, RUQ pain, jaundice); Reynolds pentad adds shock + confusion [2].
-
Biliary cirrhosis → portal hypertension: Ascites, variceal bleeding, hepatic encephalopathy [1], hepatorenal syndrome, HCC.
-
Cholangiocarcinoma is the leading cause of death in PSC — 10–20% lifetime risk, often perihilar, ~50% diagnosed within 1–2 years of PSC diagnosis. Surveillance: annual MRCP + CA 19-9.
-
Gallbladder carcinoma: Lower threshold for cholecystectomy in PSC (polyps ≥ 8 mm vs 10 mm general population) [19].
-
CRC risk is 4–5× higher in PSC-UC than UC alone → yearly colonoscopy from PSC diagnosis [3].
-
Vitamin K deficiency: Give IV vitamin K → if INR corrects = malabsorption; if not = hepatic synthetic failure. This distinction guides transplant timing.
-
Recurrent PSC post-transplant: ~20–25% at 5–10 years; confirms immune-mediated pathogenesis.
-
PSC modifies IBD: Pancolitis with rectal sparing, milder symptoms but paradoxically higher CRC risk.
Active Recall - PSC Complications
References
[1] Senior notes: felixlai.md (PSC Complications section, felix:758–759) [2] Senior notes: maxim.md (Acute cholangitis — clinical features and management, maxim:288) [3] Lecture slides: Inflammatory bowel disease.pdf (p52 — CRC risk factors in IBD; p56 — surveillance intervals) [8] Senior notes: maxim.md (Obstructive jaundice — pathophysiological disturbances, maxim:251) [9] Senior notes: felixlai.md (Cholangiocarcinoma risk factors — PSC, felix:778–779) [10] Senior notes: felixlai.md (Gallbladder cancer risk factors — PSC, felix:801) [11] Senior notes: felixlai.md (HCC risk factors — autoimmune liver diseases including PSC, felix:682) [13] Lecture slides: WCS 064 - A large liver - by Prof R Poon [20191108].doc.pdf (p5 — Cholangiocarcinoma) [19] Senior notes: maxim.md (Gallbladder polyps management — 8 mm threshold in PSC, maxim:292) [20] Senior notes: felixlai.md (Cholangiocarcinoma — biliary obstruction causing jaundice, felix:720) [24] Senior notes: felixlai.md (PSC specific complications — detailed, felix:759) [25] Senior notes: felixlai.md (Liver cirrhosis overview and causes, felix:636) [26] Senior notes: maxim.md (HCC risk factors — any cause of cirrhosis including PSC, maxim:260)
High Yield Summary
-
Definition: PSC is a chronic, progressive, immune-mediated cholestatic liver disease characterised by multifocal stricturing and fibrosis of intrahepatic and extrahepatic bile ducts, leading to biliary cirrhosis.
-
Epidemiology: Male predominance (2:1), age 30–40, much more common in Western/Northern European populations. Less common in Asia, including Hong Kong [3].
-
IBD association: ~60–80% have UC; only ~5% of UC patients develop PSC. IBD in PSC tends to be pancolitis with rectal sparing.
-
Pathophysiology: Gut-liver axis → aberrant lymphocyte homing (MAdCAM-1) → periductal "onion-skin" fibrosis → multifocal strictures → cholestasis → biliary cirrhosis.
-
Clinical features: 50% asymptomatic at diagnosis. Key symptoms: pruritus, fatigue, RUQ pain, fluctuating jaundice, recurrent cholangitis. Key signs: hepatomegaly, splenomegaly, excoriations, jaundice, signs of chronic liver disease.
-
Biochemistry: Cholestatic pattern — ALP disproportionately elevated, normal/mild AST/ALT elevation, AMA negative (distinguishes from PBC), p-ANCA often positive.
-
Cancer risk: Cholangiocarcinoma (10–20% lifetime), CRC (4–5× increased in PSC-UC → annual colonoscopy), gallbladder cancer.
-
Exclude secondary causes: IgG4-associated cholangitis (responds to steroids!), RPC, choledocholithiasis, HIV cholangiopathy, ischaemic cholangiopathy.
-
No cure except liver transplantation. UDCA is controversial and not proven to alter natural history.
High Yield Summary — Differential Diagnosis
-
PSC is a diagnosis of exclusion — you must rule out secondary sclerosing cholangitis (IgG4-SC, RPC, ischaemic, surgical, HIV cholangiopathy, stones, tumour).
-
IgG4-associated cholangitis is the most critical mimic to exclude because it responds to steroids. Always check serum IgG4.
-
PBC vs PSC: AMA positive = PBC; AMA negative + biliary strictures on MRCP = PSC. PBC affects small ducts (normal cholangiogram); PSC affects large ducts (beaded cholangiogram).
-
RPC vs PSC (Hong Kong context): RPC = intrahepatic pigment stones, left lobe predominance, parasitic association, no IBD link. PSC = immune-mediated, beaded bilateral strictures, UC association.
-
Dominant stricture in PSC must always be investigated to exclude cholangiocarcinoma — use ERCP with brush cytology ± FISH.
-
Stone vs tumour: Stone = intermittent, painful jaundice with fever. Tumour = progressive, painless jaundice with constitutional symptoms.
-
PSC-AIH overlap (~5–10%): suspect if transaminases markedly elevated; responds to immunosuppression — don't miss it.
-
Obstructive jaundice DDx by level: Hilum (PSC, RPC, Klatskin's, HCC, Mirizzi, CA GB); Mid-CBD (CA CBD, CA pancreas head); Distal CBD (periampullary CA, choledochal cyst, chronic pancreatitis).
High Yield Summary — Diagnosis of PSC
-
PSC diagnosis requires: Cholestatic biochemistry (ALP > 1.5× ULN for > 6 months) + characteristic cholangiographic findings (multifocal "beaded" strictures on MRCP) + exclusion of secondary causes.
-
MRCP is the first-line diagnostic imaging modality — non-invasive, no contrast injection, comparable accuracy to ERCP [1].
-
AMA is typically absent in PSC — its presence should prompt consideration of PBC or overlap syndrome [1].
-
Serum IgG4 must be checked to exclude IgG4-associated cholangitis (which responds to steroids) [1].
-
Liver biopsy is NOT routinely needed — reserved for small-duct PSC (normal cholangiogram) or suspected PSC-AIH overlap [1].
-
ERCP is now primarily therapeutic/problem-solving — for dominant stricture evaluation (brush cytology), balloon dilatation, and stenting. Not first-line diagnostic.
-
PTC is preferred over ERCP for hilar-level obstruction [18].
-
All PSC patients need colonoscopy to screen for IBD, regardless of GI symptoms. If IBD present → annual colonoscopy for CRC surveillance.
-
Tumour markers (CA 19-9, CEA) are baseline and for surveillance — neither sensitive nor specific alone.
-
Key biochemical pattern: ALP 3–10× ULN, ALT < 2× ULN, fluctuating bilirubin, AMA negative, p-ANCA positive.
High Yield Summary — Management of PSC
-
No proven medical therapy alters the natural history of PSC. UDCA is NOT generally recommended; immunosuppressants (steroids, azathioprine, cyclosporine, methotrexate, tacrolimus) have all failed [1].
-
Dominant strictures are managed with ERCP balloon dilatation ± short-term plastic stent. Always perform brush cytology to exclude cholangiocarcinoma. Avoid long-term stenting.
-
Acute cholangitis follows RAD: Resuscitation → Antibiotics → Drainage [2]. Antibiotics: IV Augmentin (mild) or IV Tazocin (severe) [2].
-
Pruritus stepwise: Cholestyramine → Rifampicin → Naltrexone → Sertraline. Mnemonic: "Come Running Now Sir."
-
Liver transplantation is the treatment of choice for advanced liver disease [1]. 5-year survival ~85%. PSC recurs in ~20% of allografts.
-
PSC-AIH overlap is the ONLY PSC variant that responds to immunosuppression (prednisolone + azathioprine).
-
Cancer surveillance is mandatory: Annual MRCP + CA 19-9 (CCA), yearly colonoscopy if IBD [3], annual USG (gallbladder), 6-monthly USG + AFP if cirrhotic (HCC).
-
Fat-soluble vitamins (A, D, E, K) must be supplemented. Metabolic bone disease needs DEXA and treatment.
-
Cholecystectomy for GB polyps ≥ 8 mm in PSC (lower threshold than general population's 10 mm) [19].
-
Biliary reconstructive surgery is largely abandoned — it makes subsequent transplantation harder without altering disease progression.
High Yield Summary — Complications of PSC
-
Cholestasis complications: Steatorrhoea, fat-soluble vitamin deficiency (A, D, E, K — mnemonic: ADEK), hepatic osteodystrophy (osteoporosis > osteomalacia), pruritus.
-
Dominant strictures develop in up to 60% of patients [24] — must always be investigated with ERCP brush cytology to exclude cholangiocarcinoma.
-
Recurrent bacterial cholangitis: Driven by bile stasis + strictures ± stent-related biofilm. Charcot's triad (fever, RUQ pain, jaundice); Reynolds pentad adds shock + confusion [2].
-
Biliary cirrhosis → portal hypertension: Ascites, variceal bleeding, hepatic encephalopathy [1], hepatorenal syndrome, HCC.
-
Cholangiocarcinoma is the leading cause of death in PSC — 10–20% lifetime risk, often perihilar, ~50% diagnosed within 1–2 years of PSC diagnosis. Surveillance: annual MRCP + CA 19-9.
-
Gallbladder carcinoma: Lower threshold for cholecystectomy in PSC (polyps ≥ 8 mm vs 10 mm general population) [19].
-
CRC risk is 4–5× higher in PSC-UC than UC alone → yearly colonoscopy from PSC diagnosis [3].
-
Vitamin K deficiency: Give IV vitamin K → if INR corrects = malabsorption; if not = hepatic synthetic failure. This distinction guides transplant timing.
-
Recurrent PSC post-transplant: ~20–25% at 5–10 years; confirms immune-mediated pathogenesis.
-
PSC modifies IBD: Pancolitis with rectal sparing, milder symptoms but paradoxically higher CRC risk.
Primary Biliary Cirrhosis
Primary biliary cirrhosis is a chronic autoimmune liver disease characterized by progressive destruction of intrahepatic bile ducts, leading to cholestasis, fibrosis, and eventually cirrhosis.
Recurrent Pyogenic Cholangitis
Recurrent pyogenic cholangitis is a chronic biliary condition characterized by recurrent episodes of bacterial cholangitis associated with intrahepatic pigment stone formation and biliary strictures, predominantly affecting East Asian populations.